drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01075
|
DB01181
| 1,376 | 1,532 |
[
"DDInter569",
"DDInter906"
] |
Diphenhydramine
|
Ifosfamide
|
Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed
|
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
|
Moderate
| 1 |
[
[
[
1376,
24,
1532
]
],
[
[
1376,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
1376,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
1376,
40,
307
],
[
307,
23,
1532
]
],
[
[
1376,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
1376,
64,
684
],
[
684,
24,
1532
]
],
[
[
1376,
24,
481
],
[
481,
63,
1532
]
],
[
[
1376,
24,
369
],
[
369,
24,
1532
]
],
[
[
1376,
74,
1164
],
[
1164,
24,
1532
]
],
[
[
1376,
35,
537
],
[
537,
24,
1532
]
]
] |
[
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
],
[
"Chlormezanone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
]
] |
Diphenhydramine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Diphenhydramine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Diphenhydramine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Diphenhydramine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone and Chlormezanone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Diphenhydramine (Compound) resembles Trimipramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Diphenhydramine (Compound) resembles Cyclizine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
|
DB01097
|
DB13985
| 1,377 | 546 |
[
"DDInter1033",
"DDInter1108"
] |
Leflunomide
|
Lutetium Lu 177 dotatate
|
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
|
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. Compared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times . In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated a lower whole-body retention, indicating potentially lower risk for bone marrow toxicity . The presence of a radioligand allows monitoring of treatment response post therapy and prior to next fraction of the dose delivery which may be clinically beneficial in estimating the intensity of lesion uptakes or deciding the dose for subsequent administrations . Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs . Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver . Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free survival compared to patients receiving octreotide alone and there was evidence of an overall survival benefit .
|
Major
| 2 |
[
[
[
1377,
25,
546
]
],
[
[
1377,
64,
50
],
[
50,
24,
546
]
],
[
[
1377,
25,
1683
],
[
1683,
24,
546
]
],
[
[
1377,
63,
597
],
[
597,
24,
546
]
],
[
[
1377,
24,
1430
],
[
1430,
24,
546
]
],
[
[
1377,
64,
1057
],
[
1057,
25,
546
]
],
[
[
1377,
25,
1510
],
[
1510,
25,
546
]
],
[
[
1377,
25,
676
],
[
676,
64,
546
]
],
[
[
1377,
64,
50
],
[
50,
24,
123
],
[
123,
24,
546
]
],
[
[
1377,
25,
1683
],
[
1683,
63,
66
],
[
66,
24,
546
]
]
] |
[
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
]
] |
Leflunomide may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Leflunomide may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Leflunomide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Leflunomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Leflunomide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Leflunomide may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Leflunomide may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
|
DB01222
|
DB11124
| 617 | 209 |
[
"DDInter246",
"DDInter1560"
] |
Budesonide
|
Racepinephrine
|
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol].
|
Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride.
|
Minor
| 0 |
[
[
[
617,
23,
209
]
],
[
[
617,
40,
1573
],
[
1573,
23,
209
]
],
[
[
617,
62,
688
],
[
688,
24,
209
]
],
[
[
617,
23,
659
],
[
659,
24,
209
]
],
[
[
617,
40,
1573
],
[
1573,
40,
870
],
[
870,
23,
209
]
],
[
[
617,
40,
218
],
[
218,
1,
423
],
[
423,
23,
209
]
],
[
[
617,
62,
688
],
[
688,
23,
1042
],
[
1042,
23,
209
]
],
[
[
617,
23,
659
],
[
659,
62,
1042
],
[
1042,
23,
209
]
],
[
[
617,
62,
688
],
[
688,
62,
1573
],
[
1573,
23,
209
]
],
[
[
617,
24,
1683
],
[
1683,
63,
1042
],
[
1042,
23,
209
]
]
] |
[
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Beclomethasone dipropionate"
],
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
],
[
"Ciclesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Racepinephrine"
]
]
] |
Budesonide (Compound) resembles Prednisone (Compound) and Prednisone may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Budesonide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine
Budesonide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine
Budesonide (Compound) resembles Prednisone (Compound) and Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Budesonide (Compound) resembles Beclomethasone dipropionate (Compound) and Beclomethasone dipropionate (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Budesonide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Budesonide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Budesonide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
|
DB00880
|
DB01284
| 359 | 1,042 |
[
"DDInter360",
"DDInter1782"
] |
Chlorothiazide
|
Tetracosactide
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
|
Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
|
Moderate
| 1 |
[
[
[
359,
24,
1042
]
],
[
[
359,
24,
455
],
[
455,
23,
1042
]
],
[
[
359,
24,
659
],
[
659,
62,
1042
]
],
[
[
359,
63,
1674
],
[
1674,
23,
1042
]
],
[
[
359,
40,
811
],
[
811,
24,
1042
]
],
[
[
359,
24,
761
],
[
761,
63,
1042
]
],
[
[
359,
63,
1144
],
[
1144,
24,
1042
]
],
[
[
359,
24,
1021
],
[
1021,
24,
1042
]
],
[
[
359,
62,
126
],
[
126,
24,
1042
]
],
[
[
359,
40,
178
],
[
178,
63,
1042
]
]
] |
[
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
]
] |
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Chlorothiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Chlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
|
DB01165
|
DB06655
| 1,539 | 5 |
[
"DDInter1325",
"DDInter1077"
] |
Ofloxacin
|
Liraglutide
|
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
|
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
|
Moderate
| 1 |
[
[
[
1539,
24,
5
]
],
[
[
1539,
64,
870
],
[
870,
24,
5
]
],
[
[
1539,
63,
480
],
[
480,
24,
5
]
],
[
[
1539,
24,
1491
],
[
1491,
24,
5
]
],
[
[
1539,
25,
1220
],
[
1220,
24,
5
]
],
[
[
1539,
25,
1019
],
[
1019,
63,
5
]
],
[
[
1539,
1,
872
],
[
872,
24,
5
]
],
[
[
1539,
24,
659
],
[
659,
63,
5
]
],
[
[
1539,
40,
1176
],
[
1176,
24,
5
]
],
[
[
1539,
40,
246
],
[
246,
25,
5
]
]
] |
[
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Liraglutide"
]
]
] |
Ofloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Ofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Liraglutide
|
DB00358
|
DB01244
| 1,010 | 762 |
[
"DDInter1140",
"DDInter192"
] |
Mefloquine
|
Bepridil
|
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
|
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
|
Major
| 2 |
[
[
[
1010,
25,
762
]
],
[
[
1010,
24,
675
],
[
675,
40,
762
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
762
]
],
[
[
1010,
21,
28698
],
[
28698,
60,
762
]
],
[
[
1010,
23,
112
],
[
112,
23,
762
]
],
[
[
1010,
24,
1478
],
[
1478,
63,
762
]
],
[
[
1010,
24,
480
],
[
480,
24,
762
]
],
[
[
1010,
63,
1101
],
[
1101,
24,
762
]
],
[
[
1010,
25,
593
],
[
593,
24,
762
]
],
[
[
1010,
25,
1593
],
[
1593,
64,
762
]
]
] |
[
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
]
] |
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Bepridil (Compound)
Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bepridil (Compound)
Mefloquine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Bepridil (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bepridil
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Mefloquine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Mefloquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Bepridil
|
DB00225
|
DB01136
| 457 | 772 |
[
"DDInter794",
"DDInter305"
] |
Gadodiamide
|
Carvedilol
|
Gadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels.[A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than nonionic iodinated contrast agents. Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side effects.
|
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995.
|
Moderate
| 1 |
[
[
[
457,
24,
772
]
],
[
[
457,
21,
29224
],
[
29224,
60,
772
]
],
[
[
457,
40,
808
],
[
808,
24,
772
]
],
[
[
457,
40,
1106
],
[
1106,
63,
772
]
],
[
[
457,
1,
796
],
[
796,
63,
772
]
],
[
[
457,
21,
29224
],
[
29224,
60,
1576
],
[
1576,
1,
772
]
],
[
[
457,
21,
30077
],
[
30077,
60,
417
],
[
417,
23,
772
]
],
[
[
457,
21,
29386
],
[
29386,
60,
475
],
[
475,
24,
772
]
],
[
[
457,
40,
808
],
[
808,
21,
29224
],
[
29224,
60,
772
]
],
[
[
457,
40,
622
],
[
622,
1,
1431
],
[
1431,
24,
772
]
]
] |
[
[
[
"Gadodiamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) causes {v} (Side Effect)",
"Rash erythematous"
],
[
"Rash erythematous",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadobenic acid"
],
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
],
[
"Gadoxetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) causes {v} (Side Effect)",
"Rash erythematous"
],
[
"Rash erythematous",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propranolol"
],
[
"Propranolol",
"{u} (Compound) resembles {v} (Compound)",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) causes {v} (Side Effect)",
"Fluid overload"
],
[
"Fluid overload",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiovascular disorder"
],
[
"Cardiovascular disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadobenic acid"
],
[
"Gadobenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash erythematous"
],
[
"Rash erythematous",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carvedilol"
]
],
[
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadoversetamide"
],
[
"Gadoversetamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadopentetic acid"
],
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
]
] |
Gadodiamide (Compound) causes Rash erythematous (Side Effect) and Rash erythematous (Side Effect) is caused by Carvedilol (Compound)
Gadodiamide (Compound) resembles Gadobenic acid (Compound) and Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Gadodiamide (Compound) resembles Gadofosveset trisodium (Compound) and Gadofosveset trisodium may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Gadodiamide (Compound) resembles Gadoxetic acid (Compound) and Gadoxetic acid may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Gadodiamide (Compound) causes Rash erythematous (Side Effect) and Rash erythematous (Side Effect) is caused by Propranolol (Compound) and Propranolol (Compound) resembles Carvedilol (Compound)
Gadodiamide (Compound) causes Fluid overload (Side Effect) and Fluid overload (Side Effect) is caused by Sucralfate (Compound) and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Carvedilol
Gadodiamide (Compound) causes Cardiovascular disorder (Side Effect) and Cardiovascular disorder (Side Effect) is caused by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Gadodiamide (Compound) resembles Gadobenic acid (Compound) and Gadobenic acid (Compound) causes Rash erythematous (Side Effect) and Rash erythematous (Side Effect) is caused by Carvedilol (Compound)
Gadodiamide (Compound) resembles Gadoversetamide (Compound) and Gadoversetamide (Compound) resembles Gadopentetic acid (Compound) and Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
|
DB05316
|
DB08881
| 749 | 868 |
[
"DDInter1467",
"DDInter1925"
] |
Pimavanserin
|
Vemurafenib
|
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
Major
| 2 |
[
[
[
749,
25,
868
]
],
[
[
749,
62,
112
],
[
112,
23,
868
]
],
[
[
749,
24,
578
],
[
578,
24,
868
]
],
[
[
749,
63,
480
],
[
480,
24,
868
]
],
[
[
749,
25,
760
],
[
760,
63,
868
]
],
[
[
749,
24,
286
],
[
286,
63,
868
]
],
[
[
749,
64,
478
],
[
478,
25,
868
]
],
[
[
749,
24,
823
],
[
823,
64,
868
]
],
[
[
749,
63,
1424
],
[
1424,
25,
868
]
],
[
[
749,
24,
1250
],
[
1250,
25,
868
]
]
] |
[
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
]
] |
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Pimavanserin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Pimavanserin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Vemurafenib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may lead to a major life threatening interaction when taken with Vemurafenib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Vemurafenib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Vemurafenib
|
DB00041
|
DB00851
| 1,648 | 611 |
[
"DDInter38",
"DDInter463"
] |
Aldesleukin
|
Dacarbazine
|
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
|
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
|
Major
| 2 |
[
[
[
1648,
25,
611
]
],
[
[
1648,
23,
739
],
[
739,
62,
611
]
],
[
[
1648,
23,
646
],
[
646,
23,
611
]
],
[
[
1648,
24,
141
],
[
141,
24,
611
]
],
[
[
1648,
24,
850
],
[
850,
63,
611
]
],
[
[
1648,
63,
305
],
[
305,
24,
611
]
],
[
[
1648,
25,
147
],
[
147,
24,
611
]
],
[
[
1648,
25,
770
],
[
770,
64,
611
]
],
[
[
1648,
25,
1066
],
[
1066,
25,
611
]
],
[
[
1648,
64,
1057
],
[
1057,
25,
611
]
]
] |
[
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
],
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
]
] |
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Aldesleukin may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Dacarbazine
Aldesleukin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Dacarbazine
Aldesleukin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Dacarbazine
|
DB01324
|
DB11113
| 178 | 657 |
[
"DDInter1490",
"DDInter307"
] |
Polythiazide
|
Castor oil
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)
|
Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products.
|
Moderate
| 1 |
[
[
[
178,
24,
657
]
],
[
[
178,
63,
891
],
[
891,
24,
657
]
],
[
[
178,
1,
1577
],
[
1577,
24,
657
]
],
[
[
178,
24,
1019
],
[
1019,
63,
657
]
],
[
[
178,
24,
1383
],
[
1383,
24,
657
]
],
[
[
178,
64,
57
],
[
57,
24,
657
]
],
[
[
178,
63,
891
],
[
891,
24,
1326
],
[
1326,
24,
657
]
],
[
[
178,
63,
708
],
[
708,
63,
1326
],
[
1326,
24,
657
]
],
[
[
178,
63,
613
],
[
613,
24,
927
],
[
927,
63,
657
]
],
[
[
178,
1,
1577
],
[
1577,
24,
891
],
[
891,
24,
657
]
]
] |
[
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
]
] |
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Polythiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
|
DB00486
|
DB11859
| 1,614 | 418 |
[
"DDInter1253",
"DDInter230"
] |
Nabilone
|
Brexanolone
|
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
|
As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening condition . Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083]. The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before . In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) in postpartum women susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not mediate activities directly associated with PPD like natural fluctuations in the levels of endogenous neuroactive steroids like allopregnanolone . And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare success in the weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone vs. placebo when added to standard-of-care .
|
Moderate
| 1 |
[
[
[
1614,
24,
418
]
],
[
[
1614,
24,
820
],
[
820,
24,
418
]
],
[
[
1614,
63,
1648
],
[
1648,
24,
418
]
],
[
[
1614,
40,
530
],
[
530,
24,
418
]
],
[
[
1614,
24,
820
],
[
820,
63,
100
],
[
100,
24,
418
]
],
[
[
1614,
24,
100
],
[
100,
24,
820
],
[
820,
24,
418
]
],
[
[
1614,
24,
104
],
[
104,
40,
820
],
[
820,
24,
418
]
],
[
[
1614,
63,
1648
],
[
1648,
24,
820
],
[
820,
24,
418
]
],
[
[
1614,
40,
530
],
[
530,
24,
820
],
[
820,
24,
418
]
],
[
[
1614,
24,
1311
],
[
1311,
25,
820
],
[
820,
24,
418
]
]
] |
[
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
]
] |
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
|
DB00843
|
DB01234
| 479 | 1,220 |
[
"DDInter583",
"DDInter513"
] |
Donepezil
|
Dexamethasone
|
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
|
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
|
Moderate
| 1 |
[
[
[
479,
24,
1220
]
],
[
[
479,
6,
6017
],
[
6017,
45,
1220
]
],
[
[
479,
7,
3163
],
[
3163,
46,
1220
]
],
[
[
479,
18,
2849
],
[
2849,
57,
1220
]
],
[
[
479,
21,
28835
],
[
28835,
60,
1220
]
],
[
[
479,
24,
688
],
[
688,
23,
1220
]
],
[
[
479,
62,
1018
],
[
1018,
23,
1220
]
],
[
[
479,
63,
1101
],
[
1101,
24,
1220
]
],
[
[
479,
23,
159
],
[
159,
63,
1220
]
],
[
[
479,
24,
1619
],
[
1619,
63,
1220
]
]
] |
[
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} (Compound) downregulates {v} (Gene)",
"TP53BP1"
],
[
"TP53BP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperglycaemia"
],
[
"Hyperglycaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
]
] |
Donepezil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexamethasone (Compound)
Donepezil (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Dexamethasone (Compound)
Donepezil (Compound) downregulates TP53BP1 (Gene) and TP53BP1 (Gene) is downregulated by Dexamethasone (Compound)
Donepezil (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Dexamethasone (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Donepezil may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
|
DB00445
|
DB01320
| 322 | 651 |
[
"DDInter655",
"DDInter783"
] |
Epirubicin
|
Fosphenytoin
|
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
Moderate
| 1 |
[
[
[
322,
24,
651
]
],
[
[
322,
63,
362
],
[
362,
1,
651
]
],
[
[
322,
21,
29360
],
[
29360,
60,
651
]
],
[
[
322,
63,
1101
],
[
1101,
23,
651
]
],
[
[
322,
24,
26
],
[
26,
63,
651
]
],
[
[
322,
24,
147
],
[
147,
24,
651
]
],
[
[
322,
25,
908
],
[
908,
63,
651
]
],
[
[
322,
63,
305
],
[
305,
24,
651
]
],
[
[
322,
25,
770
],
[
770,
24,
651
]
],
[
[
322,
64,
1057
],
[
1057,
24,
651
]
]
] |
[
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Face oedema"
],
[
"Face oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
]
] |
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Epirubicin (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Fosphenytoin (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosphenytoin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Epirubicin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Epirubicin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
|
DB01221
|
DB08824
| 1,190 | 591 |
[
"DDInter1007",
"DDInter959"
] |
Ketamine
|
Ioflupane I-123
|
Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.
|
Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.
|
Moderate
| 1 |
[
[
[
1190,
24,
591
]
],
[
[
1190,
21,
28722
],
[
28722,
60,
591
]
],
[
[
1190,
63,
401
],
[
401,
24,
591
]
],
[
[
1190,
24,
1311
],
[
1311,
24,
591
]
],
[
[
1190,
21,
28722
],
[
28722,
60,
109
],
[
109,
24,
591
]
],
[
[
1190,
63,
401
],
[
401,
21,
28762
],
[
28762,
60,
591
]
],
[
[
1190,
63,
999
],
[
999,
24,
109
],
[
109,
24,
591
]
],
[
[
1190,
63,
104
],
[
104,
63,
109
],
[
109,
24,
591
]
],
[
[
1190,
63,
222
],
[
222,
6,
2437
],
[
2437,
45,
591
]
],
[
[
1190,
24,
1311
],
[
1311,
21,
28722
],
[
28722,
60,
591
]
]
] |
[
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Compound)",
"Ioflupane I-123"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ioflupane I-123"
]
]
] |
Ketamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ioflupane I-123 (Compound)
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Ketamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ioflupane I-123 (Compound)
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ioflupane I-123 (Compound)
|
DB10343
|
DB11988
| 962 | 270 |
[
"DDInter160",
"DDInter1321"
] |
Bacillus calmette-guerin substrain tice live antigen
|
Ocrelizumab
|
Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis.
|
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo.
|
Major
| 2 |
[
[
[
962,
25,
270
]
],
[
[
962,
64,
134
],
[
134,
24,
270
]
],
[
[
962,
25,
1019
],
[
1019,
24,
270
]
],
[
[
962,
25,
398
],
[
398,
63,
270
]
],
[
[
962,
63,
617
],
[
617,
24,
270
]
],
[
[
962,
64,
976
],
[
976,
25,
270
]
],
[
[
962,
25,
676
],
[
676,
64,
270
]
],
[
[
962,
25,
1259
],
[
1259,
25,
270
]
],
[
[
962,
64,
134
],
[
134,
63,
1461
],
[
1461,
23,
270
]
],
[
[
962,
64,
1500
],
[
1500,
24,
713
],
[
713,
24,
270
]
]
] |
[
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tildrakizumab"
],
[
"Tildrakizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofatumumab"
],
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
]
] |
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Tildrakizumab and Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ofatumumab and Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
|
DB00398
|
DB01218
| 79 | 1,493 |
[
"DDInter1702",
"DDInter852"
] |
Sorafenib
|
Halofantrine
|
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
Major
| 2 |
[
[
[
79,
25,
1493
]
],
[
[
79,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
79,
7,
5998
],
[
5998,
46,
1493
]
],
[
[
79,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
79,
24,
479
],
[
479,
23,
1493
]
],
[
[
79,
23,
112
],
[
112,
23,
1493
]
],
[
[
79,
24,
179
],
[
179,
63,
1493
]
],
[
[
79,
24,
770
],
[
770,
24,
1493
]
],
[
[
79,
63,
867
],
[
867,
24,
1493
]
],
[
[
79,
24,
1213
],
[
1213,
64,
1493
]
]
] |
[
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
],
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
]
] |
Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Sorafenib (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Sorafenib (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Halofantrine
|
DB00998
|
DB01168
| 404 | 1,053 |
[
"DDInter788",
"DDInter1526"
] |
Frovatriptan
|
Procarbazine
|
Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
|
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
|
Major
| 2 |
[
[
[
404,
25,
1053
]
],
[
[
404,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
404,
24,
1362
],
[
1362,
63,
1053
]
],
[
[
404,
25,
1039
],
[
1039,
64,
1053
]
],
[
[
404,
64,
1494
],
[
1494,
25,
1053
]
],
[
[
404,
25,
222
],
[
222,
25,
1053
]
],
[
[
404,
63,
475
],
[
475,
25,
1053
]
],
[
[
404,
21,
28762
],
[
28762,
60,
1248
],
[
1248,
40,
1053
]
],
[
[
404,
21,
29017
],
[
29017,
60,
739
],
[
739,
23,
1053
]
],
[
[
404,
21,
29000
],
[
29000,
60,
945
],
[
945,
62,
1053
]
]
] |
[
[
[
"Frovatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atenolol"
],
[
"Atenolol",
"{u} (Compound) resembles {v} (Compound)",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating increased"
],
[
"Sweating increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
]
],
[
[
"Frovatriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Nocturia"
],
[
"Nocturia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
]
]
] |
Frovatriptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Frovatriptan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Frovatriptan may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Procarbazine
Frovatriptan may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Procarbazine
Frovatriptan may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Procarbazine
Frovatriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Procarbazine
Frovatriptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Atenolol (Compound) and Atenolol (Compound) resembles Procarbazine (Compound)
Frovatriptan (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Frovatriptan (Compound) causes Nocturia (Side Effect) and Nocturia (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
|
DB00443
|
DB12825
| 251 | 1,375 |
[
"DDInter195",
"DDInter1032"
] |
Betamethasone
|
Lefamulin
|
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
|
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
|
Moderate
| 1 |
[
[
[
251,
24,
1375
]
],
[
[
251,
24,
159
],
[
159,
63,
1375
]
],
[
[
251,
25,
976
],
[
976,
24,
1375
]
],
[
[
251,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
251,
23,
659
],
[
659,
24,
1375
]
],
[
[
251,
24,
98
],
[
98,
24,
1375
]
],
[
[
251,
40,
870
],
[
870,
24,
1375
]
],
[
[
251,
25,
676
],
[
676,
63,
1375
]
],
[
[
251,
1,
175
],
[
175,
24,
1375
]
],
[
[
251,
24,
609
],
[
609,
25,
1375
]
]
] |
[
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
] |
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin
|
DB00398
|
DB08827
| 79 | 990 |
[
"DDInter1702",
"DDInter1085"
] |
Sorafenib
|
Lomitapide
|
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
|
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
|
Major
| 2 |
[
[
[
79,
25,
990
]
],
[
[
79,
6,
8374
],
[
8374,
45,
990
]
],
[
[
79,
21,
28903
],
[
28903,
60,
990
]
],
[
[
79,
23,
1135
],
[
1135,
62,
990
]
],
[
[
79,
24,
1409
],
[
1409,
24,
990
]
],
[
[
79,
24,
1362
],
[
1362,
63,
990
]
],
[
[
79,
63,
134
],
[
134,
24,
990
]
],
[
[
79,
25,
1456
],
[
1456,
63,
990
]
],
[
[
79,
24,
888
],
[
888,
25,
990
]
],
[
[
79,
24,
1320
],
[
1320,
64,
990
]
]
] |
[
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Dry skin"
],
[
"Dry skin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
]
] |
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Sorafenib (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Lomitapide (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Lomitapide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Sorafenib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Lomitapide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may lead to a major life threatening interaction when taken with Lomitapide
|
DB06603
|
DB11113
| 39 | 657 |
[
"DDInter1387",
"DDInter307"
] |
Panobinostat
|
Castor oil
|
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
|
Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products.
|
Moderate
| 1 |
[
[
[
39,
24,
657
]
],
[
[
39,
64,
1079
],
[
1079,
24,
657
]
],
[
[
39,
25,
927
],
[
927,
63,
657
]
],
[
[
39,
25,
985
],
[
985,
24,
657
]
],
[
[
39,
63,
355
],
[
355,
24,
657
]
],
[
[
39,
64,
1079
],
[
1079,
24,
927
],
[
927,
63,
657
]
],
[
[
39,
25,
927
],
[
927,
63,
1079
],
[
1079,
24,
657
]
],
[
[
39,
64,
540
],
[
540,
25,
927
],
[
927,
63,
657
]
],
[
[
39,
64,
1491
],
[
1491,
63,
1079
],
[
1079,
24,
657
]
],
[
[
39,
25,
985
],
[
985,
64,
1079
],
[
1079,
24,
657
]
]
] |
[
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
]
] |
Panobinostat may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Panobinostat may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
|
DB01299
|
DB09122
| 698 | 1,613 |
[
"DDInter1722",
"DDInter1409"
] |
Sulfadoxine
|
Peginterferon beta-1a
|
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
|
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
|
Moderate
| 1 |
[
[
[
698,
24,
1613
]
],
[
[
698,
63,
267
],
[
267,
24,
1613
]
],
[
[
698,
1,
1029
],
[
1029,
24,
1613
]
],
[
[
698,
24,
850
],
[
850,
24,
1613
]
],
[
[
698,
24,
1662
],
[
1662,
63,
1613
]
],
[
[
698,
40,
161
],
[
161,
24,
1613
]
],
[
[
698,
63,
267
],
[
267,
24,
671
],
[
671,
24,
1613
]
],
[
[
698,
1,
1029
],
[
1029,
24,
267
],
[
267,
24,
1613
]
],
[
[
698,
1,
1247
],
[
1247,
62,
600
],
[
600,
24,
1613
]
],
[
[
698,
24,
850
],
[
850,
63,
671
],
[
671,
24,
1613
]
]
] |
[
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
]
] |
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine (Compound) resembles Sulfisoxazole (Compound) and Sulfisoxazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine (Compound) resembles Sulfisoxazole (Compound) and Sulfisoxazole may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
|
DB00758
|
DB04932
| 1,347 | 1,564 |
[
"DDInter413",
"DDInter491"
] |
Clopidogrel
|
Defibrotide
|
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
|
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
|
Major
| 2 |
[
[
[
1347,
25,
1564
]
],
[
[
1347,
23,
297
],
[
297,
62,
1564
]
],
[
[
1347,
24,
914
],
[
914,
24,
1564
]
],
[
[
1347,
63,
1100
],
[
1100,
24,
1564
]
],
[
[
1347,
24,
41
],
[
41,
63,
1564
]
],
[
[
1347,
64,
529
],
[
529,
24,
1564
]
],
[
[
1347,
64,
202
],
[
202,
25,
1564
]
],
[
[
1347,
25,
279
],
[
279,
25,
1564
]
],
[
[
1347,
24,
283
],
[
283,
64,
1564
]
],
[
[
1347,
25,
330
],
[
330,
64,
1564
]
]
] |
[
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
],
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
],
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
]
] |
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Clopidogrel may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Clopidogrel may lead to a major life threatening interaction when taken with Ardeparin and Ardeparin may lead to a major life threatening interaction when taken with Defibrotide
Clopidogrel may lead to a major life threatening interaction when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Defibrotide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Defibrotide
Clopidogrel may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Defibrotide
|
DB01220
|
DB11901
| 1,088 | 913 |
[
"DDInter1593",
"DDInter107"
] |
Rifaximin
|
Apalutamide
|
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
|
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
|
Moderate
| 1 |
[
[
[
1088,
24,
913
]
],
[
[
1088,
63,
279
],
[
279,
24,
913
]
],
[
[
1088,
24,
1320
],
[
1320,
63,
913
]
],
[
[
1088,
24,
1468
],
[
1468,
24,
913
]
],
[
[
1088,
24,
1612
],
[
1612,
25,
913
]
],
[
[
1088,
24,
124
],
[
124,
64,
913
]
],
[
[
1088,
63,
279
],
[
279,
64,
112
],
[
112,
23,
913
]
],
[
[
1088,
24,
1320
],
[
1320,
62,
608
],
[
608,
23,
913
]
],
[
[
1088,
24,
1468
],
[
1468,
63,
112
],
[
112,
23,
913
]
],
[
[
1088,
24,
1206
],
[
1206,
63,
201
],
[
201,
24,
913
]
]
] |
[
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
],
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
]
] |
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may lead to a major life threatening interaction when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Montelukast and Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
|
DB00909
|
DB08912
| 306 | 1,040 |
[
"DDInter1971",
"DDInter462"
] |
Zonisamide
|
Dabrafenib
|
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
|
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
|
Moderate
| 1 |
[
[
[
306,
24,
1040
]
],
[
[
306,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
306,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
306,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
306,
24,
478
],
[
478,
24,
1040
]
],
[
[
306,
63,
752
],
[
752,
24,
1040
]
],
[
[
306,
24,
384
],
[
384,
63,
1040
]
],
[
[
306,
64,
1645
],
[
1645,
24,
1040
]
],
[
[
306,
24,
1017
],
[
1017,
64,
1040
]
],
[
[
306,
6,
8374
],
[
8374,
45,
168
],
[
168,
23,
1040
]
]
] |
[
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zonisamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
]
] |
Zonisamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Zonisamide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Zonisamide may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Dabrafenib
Zonisamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
|
DB00553
|
DB00563
| 92 | 663 |
[
"DDInter1177",
"DDInter1174"
] |
Methoxsalen
|
Methotrexate
|
A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
|
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
|
Moderate
| 1 |
[
[
[
92,
24,
663
]
],
[
[
92,
5,
11587
],
[
11587,
44,
663
]
],
[
[
92,
21,
28681
],
[
28681,
60,
663
]
],
[
[
92,
24,
1622
],
[
1622,
63,
663
]
],
[
[
92,
25,
876
],
[
876,
63,
663
]
],
[
[
92,
63,
161
],
[
161,
24,
663
]
],
[
[
92,
24,
1014
],
[
1014,
24,
663
]
],
[
[
92,
24,
1274
],
[
1274,
64,
663
]
],
[
[
92,
25,
213
],
[
213,
64,
663
]
],
[
[
92,
63,
640
],
[
640,
25,
663
]
]
] |
[
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} (Compound) treats {v} (Disease)",
"psoriasis"
],
[
"psoriasis",
"{u} (Disease) is treated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
]
] |
Methoxsalen (Compound) treats psoriasis (Disease) and psoriasis (Disease) is treated by Methotrexate (Compound)
Methoxsalen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Methoxsalen may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Methotrexate
Methoxsalen may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methotrexate
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Methotrexate
|
DB01174
|
DB01268
| 697 | 1,151 |
[
"DDInter1442",
"DDInter1731"
] |
Phenobarbital
|
Sunitinib
|
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
|
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
|
Major
| 2 |
[
[
[
697,
25,
1151
]
],
[
[
697,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
697,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
697,
21,
29327
],
[
29327,
60,
1151
]
],
[
[
697,
63,
112
],
[
112,
23,
1151
]
],
[
[
697,
24,
1250
],
[
1250,
63,
1151
]
],
[
[
697,
63,
1424
],
[
1424,
24,
1151
]
],
[
[
697,
24,
392
],
[
392,
24,
1151
]
],
[
[
697,
25,
1213
],
[
1213,
24,
1151
]
],
[
[
697,
25,
792
],
[
792,
63,
1151
]
]
] |
[
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Renal failure"
],
[
"Renal failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] |
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Phenobarbital (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Phenobarbital (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Sunitinib (Compound)
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Phenobarbital may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Phenobarbital may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
|
DB00486
|
DB00590
| 1,614 | 1,433 |
[
"DDInter1253",
"DDInter592"
] |
Nabilone
|
Doxazosin
|
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
|
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
|
Moderate
| 1 |
[
[
[
1614,
24,
1433
]
],
[
[
1614,
24,
195
],
[
195,
1,
1433
]
],
[
[
1614,
63,
1205
],
[
1205,
40,
1433
]
],
[
[
1614,
63,
472
],
[
472,
1,
1433
]
],
[
[
1614,
21,
28698
],
[
28698,
60,
1433
]
],
[
[
1614,
24,
407
],
[
407,
63,
1433
]
],
[
[
1614,
63,
475
],
[
475,
24,
1433
]
],
[
[
1614,
40,
530
],
[
530,
24,
1433
]
],
[
[
1614,
24,
195
],
[
195,
1,
1205
],
[
1205,
40,
1433
]
],
[
[
1614,
63,
1205
],
[
1205,
40,
195
],
[
195,
1,
1433
]
]
] |
[
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
],
[
"Terazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
],
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
],
[
"Terazosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
],
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Terazosin"
],
[
"Terazosin",
"{u} (Compound) resembles {v} (Compound)",
"Doxazosin"
]
]
] |
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Terazosin and Terazosin (Compound) resembles Doxazosin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Doxazosin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alfuzosin and Alfuzosin (Compound) resembles Doxazosin (Compound)
Nabilone (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Doxazosin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Terazosin and Terazosin (Compound) resembles Prazosin (Compound) and Prazosin (Compound) resembles Doxazosin (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Terazosin (Compound) and Terazosin (Compound) resembles Doxazosin (Compound)
|
DB06650
|
DB08913
| 1,500 | 1,186 |
[
"DDInter1324",
"DDInter1561"
] |
Ofatumumab
|
Radium Ra 223 dichloride
|
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-
|
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
|
Moderate
| 1 |
[
[
[
1500,
24,
1186
]
],
[
[
1500,
24,
1362
],
[
1362,
63,
1186
]
],
[
[
1500,
63,
599
],
[
599,
24,
1186
]
],
[
[
1500,
64,
1377
],
[
1377,
24,
1186
]
],
[
[
1500,
25,
1510
],
[
1510,
24,
1186
]
],
[
[
1500,
25,
1259
],
[
1259,
63,
1186
]
],
[
[
1500,
24,
1362
],
[
1362,
63,
37
],
[
37,
24,
1186
]
],
[
[
1500,
63,
599
],
[
599,
24,
37
],
[
37,
24,
1186
]
],
[
[
1500,
63,
4
],
[
4,
63,
37
],
[
37,
24,
1186
]
],
[
[
1500,
64,
1377
],
[
1377,
21,
28722
],
[
28722,
60,
1186
]
]
] |
[
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
]
] |
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Ofatumumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
|
DB05676
|
DB11718
| 1,513 | 927 |
[
"DDInter111",
"DDInter640"
] |
Apremilast
|
Encorafenib
|
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
|
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
|
Moderate
| 1 |
[
[
[
1513,
24,
927
]
],
[
[
1513,
63,
536
],
[
536,
24,
927
]
],
[
[
1513,
24,
861
],
[
861,
63,
927
]
],
[
[
1513,
24,
1678
],
[
1678,
24,
927
]
],
[
[
1513,
62,
307
],
[
307,
25,
927
]
],
[
[
1513,
24,
655
],
[
655,
25,
927
]
],
[
[
1513,
64,
759
],
[
759,
25,
927
]
],
[
[
1513,
24,
1017
],
[
1017,
64,
927
]
],
[
[
1513,
63,
152
],
[
152,
25,
927
]
],
[
[
1513,
25,
129
],
[
129,
25,
927
]
]
] |
[
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
],
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Apremilast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] |
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad and Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Apremilast may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may lead to a major life threatening interaction when taken with Encorafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may lead to a major life threatening interaction when taken with Encorafenib
Apremilast may lead to a major life threatening interaction when taken with Primidone and Primidone may lead to a major life threatening interaction when taken with Encorafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Bosentan and Bosentan may lead to a major life threatening interaction when taken with Encorafenib
Apremilast may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Encorafenib
|
DB01394
|
DB11828
| 1,554 | 1,406 |
[
"DDInter431",
"DDInter1281"
] |
Colchicine
|
Neratinib
|
Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.
|
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
|
Major
| 2 |
[
[
[
1554,
25,
1406
]
],
[
[
1554,
64,
392
],
[
392,
24,
1406
]
],
[
[
1554,
24,
1510
],
[
1510,
24,
1406
]
],
[
[
1554,
25,
1456
],
[
1456,
24,
1406
]
],
[
[
1554,
63,
134
],
[
134,
24,
1406
]
],
[
[
1554,
25,
971
],
[
971,
63,
1406
]
],
[
[
1554,
25,
1593
],
[
1593,
25,
1406
]
],
[
[
1554,
25,
283
],
[
283,
64,
1406
]
],
[
[
1554,
64,
609
],
[
609,
25,
1406
]
],
[
[
1554,
63,
597
],
[
597,
25,
1406
]
]
] |
[
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] |
Colchicine may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Colchicine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Colchicine may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Colchicine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Colchicine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Colchicine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Neratinib
|
DB00092
|
DB00497
| 58 | 828 |
[
"DDInter40",
"DDInter1366"
] |
Alefacept
|
Oxycodone
|
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
|
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.
|
Moderate
| 1 |
[
[
[
58,
24,
828
]
],
[
[
58,
24,
812
],
[
812,
63,
828
]
],
[
[
58,
63,
1648
],
[
1648,
24,
828
]
],
[
[
58,
25,
976
],
[
976,
63,
828
]
],
[
[
58,
24,
1101
],
[
1101,
24,
828
]
],
[
[
58,
24,
1419
],
[
1419,
64,
828
]
],
[
[
58,
24,
812
],
[
812,
64,
908
],
[
908,
63,
828
]
],
[
[
58,
63,
1648
],
[
1648,
24,
421
],
[
421,
1,
828
]
],
[
[
58,
24,
980
],
[
980,
63,
267
],
[
267,
64,
828
]
],
[
[
58,
24,
908
],
[
908,
25,
812
],
[
812,
63,
828
]
]
] |
[
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
],
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
],
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
],
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
]
] |
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab and Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Alefacept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Oxycodone
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab and Siltuximab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxycodone (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may lead to a major life threatening interaction when taken with Oxycodone
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Siltuximab and Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
|
DB01259
|
DB08864
| 392 | 786 |
[
"DDInter1024",
"DDInter1595"
] |
Lapatinib
|
Rilpivirine
|
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
|
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.
|
Moderate
| 1 |
[
[
[
392,
24,
786
]
],
[
[
392,
24,
655
],
[
655,
1,
786
]
],
[
[
392,
6,
8374
],
[
8374,
45,
786
]
],
[
[
392,
21,
28734
],
[
28734,
60,
786
]
],
[
[
392,
62,
112
],
[
112,
23,
786
]
],
[
[
392,
63,
522
],
[
522,
24,
786
]
],
[
[
392,
24,
1017
],
[
1017,
63,
786
]
],
[
[
392,
24,
1342
],
[
1342,
24,
786
]
],
[
[
392,
64,
609
],
[
609,
24,
786
]
],
[
[
392,
25,
384
],
[
384,
63,
786
]
]
] |
[
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} (Compound) resembles {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Immune system disorder"
],
[
"Immune system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
]
] |
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Lapatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Lapatinib (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Rilpivirine (Compound)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Lapatinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Lapatinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
|
DB00774
|
DB01069
| 1,577 | 401 |
[
"DDInter889",
"DDInter1533"
] |
Hydroflumethiazide
|
Promethazine
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
|
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
|
Moderate
| 1 |
[
[
[
1577,
24,
401
]
],
[
[
1577,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1577,
24,
104
],
[
104,
24,
401
]
],
[
[
1577,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1577,
24,
286
],
[
286,
62,
401
]
],
[
[
1577,
63,
1614
],
[
1614,
24,
401
]
],
[
[
1577,
40,
504
],
[
504,
24,
401
]
],
[
[
1577,
62,
352
],
[
352,
24,
401
]
],
[
[
1577,
23,
1123
],
[
1123,
24,
401
]
],
[
[
1577,
23,
1511
],
[
1511,
63,
401
]
]
] |
[
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] |
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Hydroflumethiazide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Promethazine
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Hydroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
|
DB00539
|
DB09330
| 11 | 985 |
[
"DDInter1837",
"DDInter1352"
] |
Toremifene
|
Osimertinib
|
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
|
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
|
Major
| 2 |
[
[
[
11,
25,
985
]
],
[
[
11,
23,
1247
],
[
1247,
23,
985
]
],
[
[
11,
24,
1478
],
[
1478,
24,
985
]
],
[
[
11,
24,
1598
],
[
1598,
63,
985
]
],
[
[
11,
64,
1181
],
[
1181,
24,
985
]
],
[
[
11,
63,
62
],
[
62,
24,
985
]
],
[
[
11,
25,
1220
],
[
1220,
24,
985
]
],
[
[
11,
25,
1383
],
[
1383,
63,
985
]
],
[
[
11,
35,
543
],
[
543,
24,
985
]
],
[
[
11,
25,
843
],
[
843,
25,
985
]
]
] |
[
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
],
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] |
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene (Compound) resembles Loperamide (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Toremifene may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib
|
DB00230
|
DB01619
| 784 | 830 |
[
"DDInter1516",
"DDInter1441"
] |
Pregabalin
|
Phenindamine
|
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.
|
Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures.
|
Moderate
| 1 |
[
[
[
784,
24,
830
]
],
[
[
784,
24,
537
],
[
537,
40,
830
]
],
[
[
784,
24,
13
],
[
13,
24,
830
]
],
[
[
784,
24,
104
],
[
104,
1,
830
]
],
[
[
784,
24,
407
],
[
407,
63,
830
]
],
[
[
784,
25,
475
],
[
475,
24,
830
]
],
[
[
784,
24,
537
],
[
537,
63,
1251
],
[
1251,
1,
830
]
],
[
[
784,
24,
1219
],
[
1219,
74,
1251
],
[
1251,
1,
830
]
],
[
[
784,
24,
104
],
[
104,
40,
1251
],
[
1251,
1,
830
]
],
[
[
784,
24,
701
],
[
701,
24,
1251
],
[
1251,
1,
830
]
]
] |
[
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
]
] |
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Phenindamine (Compound)
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Pregabalin may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Mirtazapine (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Mirtazapine (Compound) and Mirtazapine (Compound) resembles Phenindamine (Compound)
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
|
DB00414
|
DB11827
| 590 | 433 |
[
"DDInter16",
"DDInter669"
] |
Acetohexamide
|
Ertugliflozin
|
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
|
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
|
Moderate
| 1 |
[
[
[
590,
24,
433
]
],
[
[
590,
62,
1103
],
[
1103,
23,
433
]
],
[
[
590,
24,
1020
],
[
1020,
24,
433
]
],
[
[
590,
24,
1654
],
[
1654,
63,
433
]
],
[
[
590,
63,
695
],
[
695,
24,
433
]
],
[
[
590,
64,
1176
],
[
1176,
24,
433
]
],
[
[
590,
25,
255
],
[
255,
63,
433
]
],
[
[
590,
25,
956
],
[
956,
24,
433
]
],
[
[
590,
23,
1551
],
[
1551,
24,
433
]
],
[
[
590,
25,
246
],
[
246,
25,
433
]
]
] |
[
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ertugliflozin"
]
]
] |
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Acetohexamide may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Ertugliflozin
|
DB09083
|
DB11730
| 880 | 351 |
[
"DDInter996",
"DDInter1588"
] |
Ivabradine
|
Ribociclib
|
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta
|
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
|
Major
| 2 |
[
[
[
880,
25,
351
]
],
[
[
880,
25,
283
],
[
283,
62,
351
]
],
[
[
880,
63,
597
],
[
597,
24,
351
]
],
[
[
880,
24,
98
],
[
98,
24,
351
]
],
[
[
880,
64,
1491
],
[
1491,
24,
351
]
],
[
[
880,
24,
1017
],
[
1017,
63,
351
]
],
[
[
880,
64,
129
],
[
129,
25,
351
]
],
[
[
880,
25,
1297
],
[
1297,
64,
351
]
],
[
[
880,
25,
985
],
[
985,
25,
351
]
],
[
[
880,
63,
1478
],
[
1478,
25,
351
]
]
] |
[
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] |
Ivabradine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ivabradine may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ivabradine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Ivabradine may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib
Ivabradine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Ribociclib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Ribociclib
|
DB04868
|
DB06207
| 478 | 910 |
[
"DDInter1293",
"DDInter1667"
] |
Nilotinib
|
Silodosin
|
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
|
Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by the FDA in October 2008 and it is also approved in Europe and Canada. Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have a negative impact on the quality of life of patients. Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction.
|
Moderate
| 1 |
[
[
[
478,
24,
910
]
],
[
[
478,
6,
8374
],
[
8374,
45,
910
]
],
[
[
478,
21,
28921
],
[
28921,
60,
910
]
],
[
[
478,
63,
353
],
[
353,
24,
910
]
],
[
[
478,
64,
1220
],
[
1220,
24,
910
]
],
[
[
478,
25,
484
],
[
484,
63,
910
]
],
[
[
478,
24,
159
],
[
159,
63,
910
]
],
[
[
478,
74,
1419
],
[
1419,
24,
910
]
],
[
[
478,
25,
760
],
[
760,
64,
910
]
],
[
[
478,
64,
609
],
[
609,
25,
910
]
]
] |
[
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Silodosin"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Silodosin"
]
]
] |
Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound)
Nilotinib (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Silodosin (Compound)
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Silodosin
Nilotinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Silodosin
Nilotinib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Silodosin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Silodosin
Nilotinib (Compound) resembles Imatinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Silodosin
Nilotinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Silodosin
Nilotinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Silodosin
|
DB01110
|
DB04908
| 86 | 1,671 |
[
"DDInter1209",
"DDInter741"
] |
Miconazole
|
Flibanserin
|
Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m
|
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
|
Moderate
| 1 |
[
[
[
86,
24,
1671
]
],
[
[
86,
24,
1478
],
[
1478,
63,
1671
]
],
[
[
86,
63,
303
],
[
303,
24,
1671
]
],
[
[
86,
62,
1413
],
[
1413,
24,
1671
]
],
[
[
86,
24,
478
],
[
478,
24,
1671
]
],
[
[
86,
63,
600
],
[
600,
25,
1671
]
],
[
[
86,
24,
1593
],
[
1593,
64,
1671
]
],
[
[
86,
24,
1478
],
[
1478,
23,
1135
],
[
1135,
62,
1671
]
],
[
[
86,
63,
303
],
[
303,
24,
98
],
[
98,
63,
1671
]
],
[
[
86,
62,
1413
],
[
1413,
24,
741
],
[
741,
63,
1671
]
]
] |
[
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
]
] |
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Miconazole may cause a minor interaction that can limit clinical effects when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Flibanserin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Flibanserin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Miconazole may cause a minor interaction that can limit clinical effects when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
|
DB01118
|
DB01218
| 33 | 1,493 |
[
"DDInter76",
"DDInter852"
] |
Amiodarone
|
Halofantrine
|
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
Major
| 2 |
[
[
[
33,
25,
1493
]
],
[
[
33,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
33,
7,
5998
],
[
5998,
46,
1493
]
],
[
[
33,
18,
2183
],
[
2183,
57,
1493
]
],
[
[
33,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
33,
63,
112
],
[
112,
23,
1493
]
],
[
[
33,
25,
116
],
[
116,
63,
1493
]
],
[
[
33,
63,
770
],
[
770,
24,
1493
]
],
[
[
33,
24,
1017
],
[
1017,
63,
1493
]
],
[
[
33,
64,
543
],
[
543,
24,
1493
]
]
] |
[
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
]
] |
Amiodarone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Amiodarone (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Amiodarone (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Amiodarone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Amiodarone may lead to a major life threatening interaction when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
Amiodarone may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine
|
DB00758
|
DB09065
| 1,347 | 760 |
[
"DDInter413",
"DDInter424"
] |
Clopidogrel
|
Cobicistat
|
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
|
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
|
Major
| 2 |
[
[
[
1347,
25,
760
]
],
[
[
1347,
63,
1230
],
[
1230,
23,
760
]
],
[
[
1347,
24,
318
],
[
318,
23,
760
]
],
[
[
1347,
63,
534
],
[
534,
24,
760
]
],
[
[
1347,
24,
609
],
[
609,
24,
760
]
],
[
[
1347,
25,
1421
],
[
1421,
63,
760
]
],
[
[
1347,
25,
1047
],
[
1047,
24,
760
]
],
[
[
1347,
24,
1496
],
[
1496,
63,
760
]
],
[
[
1347,
23,
671
],
[
671,
24,
760
]
],
[
[
1347,
62,
888
],
[
888,
24,
760
]
]
] |
[
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
]
] |
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Clopidogrel may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Clopidogrel may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
|
DB08870
|
DB08880
| 850 | 1,510 |
[
"DDInter228",
"DDInter1771"
] |
Brentuximab vedotin
|
Teriflunomide
|
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg
|
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
|
Major
| 2 |
[
[
[
850,
25,
1510
]
],
[
[
850,
24,
129
],
[
129,
63,
1510
]
],
[
[
850,
63,
1136
],
[
1136,
24,
1510
]
],
[
[
850,
63,
208
],
[
208,
25,
1510
]
],
[
[
850,
24,
36
],
[
36,
25,
1510
]
],
[
[
850,
24,
637
],
[
637,
64,
1510
]
],
[
[
850,
64,
1066
],
[
1066,
25,
1510
]
],
[
[
850,
25,
375
],
[
375,
64,
1510
]
],
[
[
850,
24,
129
],
[
129,
62,
608
],
[
608,
23,
1510
]
],
[
[
850,
24,
1033
],
[
1033,
64,
129
],
[
129,
63,
1510
]
]
] |
[
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
],
[
"Mephenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teriflunomide"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
]
] |
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin and Mephenytoin may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
|
DB00774
|
DB01017
| 1,577 | 1,669 |
[
"DDInter889",
"DDInter1224"
] |
Hydroflumethiazide
|
Minocycline
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
|
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971.
|
Minor
| 0 |
[
[
[
1577,
23,
1669
]
],
[
[
1577,
62,
1572
],
[
1572,
1,
1669
]
],
[
[
1577,
62,
1545
],
[
1545,
40,
1669
]
],
[
[
1577,
40,
504
],
[
504,
23,
1669
]
],
[
[
1577,
1,
359
],
[
359,
23,
1669
]
],
[
[
1577,
40,
674
],
[
674,
62,
1669
]
],
[
[
1577,
24,
1254
],
[
1254,
63,
1669
]
],
[
[
1577,
63,
663
],
[
663,
24,
1669
]
],
[
[
1577,
62,
126
],
[
126,
24,
1669
]
],
[
[
1577,
25,
213
],
[
213,
25,
1669
]
]
] |
[
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Hydroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minocycline"
]
]
] |
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Minocycline (Compound)
Hydroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline
Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline
Hydroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Hydroflumethiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Minocycline
|
DB00831
|
DB09038
| 1,178 | 1,450 |
[
"DDInter1866",
"DDInter636"
] |
Trifluoperazine
|
Empagliflozin
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
|
Moderate
| 1 |
[
[
[
1178,
24,
1450
]
],
[
[
1178,
63,
485
],
[
485,
24,
1450
]
],
[
[
1178,
24,
659
],
[
659,
63,
1450
]
],
[
[
1178,
24,
688
],
[
688,
24,
1450
]
],
[
[
1178,
35,
104
],
[
104,
24,
1450
]
],
[
[
1178,
40,
9
],
[
9,
24,
1450
]
],
[
[
1178,
62,
417
],
[
417,
24,
1450
]
],
[
[
1178,
1,
684
],
[
684,
24,
1450
]
],
[
[
1178,
25,
1154
],
[
1154,
24,
1450
]
],
[
[
1178,
25,
351
],
[
351,
63,
1450
]
]
] |
[
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
]
] |
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine (Compound) resembles Methdilazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Trifluoperazine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
|
DB00446
|
DB08889
| 597 | 350 |
[
"DDInter351",
"DDInter299"
] |
Chloramphenicol
|
Carfilzomib
|
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
|
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
|
Moderate
| 1 |
[
[
[
597,
24,
350
]
],
[
[
597,
23,
833
],
[
833,
1,
350
]
],
[
[
597,
21,
28762
],
[
28762,
60,
350
]
],
[
[
597,
24,
1060
],
[
1060,
63,
350
]
],
[
[
597,
63,
482
],
[
482,
24,
350
]
],
[
[
597,
24,
310
],
[
310,
24,
350
]
],
[
[
597,
23,
1627
],
[
1627,
63,
350
]
],
[
[
597,
63,
581
],
[
581,
25,
350
]
],
[
[
597,
64,
1064
],
[
1064,
25,
350
]
],
[
[
597,
25,
990
],
[
990,
25,
350
]
]
] |
[
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
]
] |
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Lopinavir and Lopinavir (Compound) resembles Carfilzomib (Compound)
Chloramphenicol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Carfilzomib
Chloramphenicol may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib
Chloramphenicol may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Carfilzomib
|
DB01069
|
DB01175
| 401 | 318 |
[
"DDInter1533",
"DDInter672"
] |
Promethazine
|
Escitalopram
|
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
|
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
|
Major
| 2 |
[
[
[
401,
25,
318
]
],
[
[
401,
64,
1230
],
[
1230,
1,
318
]
],
[
[
401,
6,
5214
],
[
5214,
45,
318
]
],
[
[
401,
21,
28719
],
[
28719,
60,
318
]
],
[
[
401,
62,
112
],
[
112,
23,
318
]
],
[
[
401,
63,
1419
],
[
1419,
23,
318
]
],
[
[
401,
24,
760
],
[
760,
62,
318
]
],
[
[
401,
63,
999
],
[
999,
24,
318
]
],
[
[
401,
24,
1376
],
[
1376,
24,
318
]
],
[
[
401,
24,
1609
],
[
1609,
63,
318
]
]
] |
[
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
]
] |
Promethazine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Promethazine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Escitalopram (Compound)
Promethazine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Escitalopram (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
|
DB00618
|
DB01592
| 1,572 | 1,596 |
[
"DDInter498",
"DDInter975"
] |
Demeclocycline
|
Iron
|
A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
|
A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
|
Moderate
| 1 |
[
[
[
1572,
24,
1596
]
],
[
[
1572,
24,
1193
],
[
1193,
62,
1596
]
],
[
[
1572,
24,
1096
],
[
1096,
23,
1596
]
],
[
[
1572,
40,
964
],
[
964,
24,
1596
]
],
[
[
1572,
24,
1384
],
[
1384,
63,
1596
]
],
[
[
1572,
1,
1669
],
[
1669,
24,
1596
]
],
[
[
1572,
24,
1117
],
[
1117,
24,
1596
]
],
[
[
1572,
24,
1193
],
[
1193,
62,
1096
],
[
1096,
23,
1596
]
],
[
[
1572,
24,
1096
],
[
1096,
21,
29243
],
[
29243,
60,
1596
]
],
[
[
1572,
40,
964
],
[
964,
24,
1096
],
[
1096,
23,
1596
]
]
] |
[
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
],
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Wheezing"
],
[
"Wheezing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iron"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
]
]
] |
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Iron
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Iron
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Iron
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Iron
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Iron
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Iron (Compound)
Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Iron
|
DB00357
|
DB06772
| 1,051 | 310 |
[
"DDInter71",
"DDInter259"
] |
Aminoglutethimide
|
Cabazitaxel
|
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
|
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
|
Moderate
| 1 |
[
[
[
1051,
24,
310
]
],
[
[
1051,
24,
973
],
[
973,
24,
310
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
310
]
],
[
[
1051,
21,
28766
],
[
28766,
60,
310
]
],
[
[
1051,
24,
307
],
[
307,
23,
310
]
],
[
[
1051,
24,
800
],
[
800,
63,
310
]
],
[
[
1051,
63,
798
],
[
798,
24,
310
]
],
[
[
1051,
62,
1101
],
[
1101,
24,
310
]
],
[
[
1051,
24,
976
],
[
976,
64,
310
]
],
[
[
1051,
24,
973
],
[
973,
40,
301
],
[
301,
40,
310
]
]
] |
[
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} (Compound) resembles {v} (Compound)",
"Docetaxel"
],
[
"Docetaxel",
"{u} (Compound) resembles {v} (Compound)",
"Cabazitaxel"
]
]
] |
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Aminoglutethimide (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Cabazitaxel (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Cabazitaxel
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel (Compound) resembles Docetaxel (Compound) and Docetaxel (Compound) resembles Cabazitaxel (Compound)
|
DB00819
|
DB00855
| 471 | 213 |
[
"DDInter15",
"DDInter72"
] |
Acetazolamide
|
Aminolevulinic acid
|
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
|
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
|
Major
| 2 |
[
[
[
471,
25,
213
]
],
[
[
471,
21,
28722
],
[
28722,
60,
213
]
],
[
[
471,
62,
1572
],
[
1572,
25,
213
]
],
[
[
471,
63,
245
],
[
245,
25,
213
]
],
[
[
471,
24,
1411
],
[
1411,
64,
213
]
],
[
[
471,
23,
1669
],
[
1669,
64,
213
]
],
[
[
471,
24,
842
],
[
842,
75,
213
]
],
[
[
471,
21,
28722
],
[
28722,
60,
191
],
[
191,
1,
213
]
],
[
[
471,
21,
29164
],
[
29164,
60,
1577
],
[
1577,
25,
213
]
],
[
[
471,
21,
28828
],
[
28828,
60,
11546
],
[
11546,
40,
213
]
]
] |
[
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminocaproic acid"
],
[
"Aminocaproic acid",
"{u} (Compound) resembles {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity"
],
[
"Photosensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azelaic Acid"
],
[
"Azelaic Acid",
"{u} (Compound) resembles {v} (Compound)",
"Aminolevulinic acid"
]
]
] |
Acetazolamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Aminolevulinic acid (Compound)
Acetazolamide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may lead to a major life threatening interaction when taken with Aminolevulinic acid
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Acetazolamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate (Compound) resembles Aminolevulinic acid (Compound) and Methyl aminolevulinate may lead to a major life threatening interaction when taken with Aminolevulinic acid
Acetazolamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Aminocaproic acid (Compound) and Aminocaproic acid (Compound) resembles Aminolevulinic acid (Compound)
Acetazolamide (Compound) causes Photosensitivity (Side Effect) and Photosensitivity (Side Effect) is caused by Hydroflumethiazide (Compound) and Hydroflumethiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Acetazolamide (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Azelaic Acid (Compound) and Azelaic Acid (Compound) resembles Aminolevulinic acid (Compound)
|
DB00682
|
DB08893
| 126 | 271 |
[
"DDInter1951",
"DDInter1229"
] |
Warfarin
|
Mirabegron
|
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
|
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other jurisdictions across the globe, including Canada, the EU, and Japan.
|
Minor
| 0 |
[
[
[
126,
23,
271
]
],
[
[
126,
24,
371
],
[
371,
40,
271
]
],
[
[
126,
62,
1523
],
[
1523,
40,
271
]
],
[
[
126,
6,
1829
],
[
1829,
45,
271
]
],
[
[
126,
24,
129
],
[
129,
62,
271
]
],
[
[
126,
24,
1220
],
[
1220,
23,
271
]
],
[
[
126,
63,
723
],
[
723,
23,
271
]
],
[
[
126,
25,
86
],
[
86,
23,
271
]
],
[
[
126,
64,
600
],
[
600,
23,
271
]
],
[
[
126,
23,
918
],
[
918,
23,
271
]
]
] |
[
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
]
] |
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Mirabegron (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Labetalol and Labetalol (Compound) resembles Mirabegron (Compound)
Warfarin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Mirabegron (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Warfarin may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Warfarin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bicalutamide and Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
|
DB08890
|
DB09104
| 16 | 286 |
[
"DDInter1069",
"DDInter1118"
] |
Linaclotide
|
Magnesium hydroxide
|
Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin derived from _Escherichia coli_, the first natural ligand that activates GC-C. Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012. It gained EMA and Health Canada approval on November 26, 2012 and December 3, 2013, respectively. Linaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation
|
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
|
Minor
| 0 |
[
[
[
16,
23,
286
]
],
[
[
16,
62,
831
],
[
831,
23,
286
]
],
[
[
16,
63,
542
],
[
542,
24,
286
]
],
[
[
16,
24,
320
],
[
320,
24,
286
]
],
[
[
16,
23,
28
],
[
28,
24,
286
]
],
[
[
16,
62,
544
],
[
544,
24,
286
]
],
[
[
16,
62,
831
],
[
831,
23,
752
],
[
752,
23,
286
]
],
[
[
16,
62,
848
],
[
848,
63,
109
],
[
109,
23,
286
]
],
[
[
16,
62,
355
],
[
355,
24,
820
],
[
820,
23,
286
]
],
[
[
16,
63,
542
],
[
542,
24,
1482
],
[
1482,
23,
286
]
]
] |
[
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
],
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Linaclotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
]
] |
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Linaclotide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Linaclotide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine and Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Linaclotide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
|
DB00889
|
DB11978
| 1,133 | 124 |
[
"DDInter840",
"DDInter822"
] |
Granisetron
|
Glasdegib
|
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
|
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
|
Moderate
| 1 |
[
[
[
1133,
24,
124
]
],
[
[
1133,
23,
1247
],
[
1247,
23,
124
]
],
[
[
1133,
24,
1079
],
[
1079,
24,
124
]
],
[
[
1133,
24,
1032
],
[
1032,
63,
124
]
],
[
[
1133,
63,
475
],
[
475,
24,
124
]
],
[
[
1133,
25,
180
],
[
180,
63,
124
]
],
[
[
1133,
64,
87
],
[
87,
24,
124
]
],
[
[
1133,
25,
1237
],
[
1237,
24,
124
]
],
[
[
1133,
25,
996
],
[
996,
25,
124
]
],
[
[
1133,
64,
702
],
[
702,
25,
124
]
]
] |
[
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
]
] |
Granisetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Granisetron may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Granisetron may lead to a major life threatening interaction when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Granisetron may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Granisetron may lead to a major life threatening interaction when taken with Bedaquiline and Bedaquiline may lead to a major life threatening interaction when taken with Glasdegib
Granisetron may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib
|
DB00564
|
DB04868
| 1,236 | 478 |
[
"DDInter293",
"DDInter1293"
] |
Carbamazepine
|
Nilotinib
|
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.
|
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
|
Major
| 2 |
[
[
[
1236,
25,
478
]
],
[
[
1236,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1236,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1236,
18,
10375
],
[
10375,
57,
478
]
],
[
[
1236,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1236,
25,
1135
],
[
1135,
62,
478
]
],
[
[
1236,
40,
307
],
[
307,
23,
478
]
],
[
[
1236,
24,
112
],
[
112,
23,
478
]
],
[
[
1236,
25,
313
],
[
313,
63,
478
]
],
[
[
1236,
63,
510
],
[
510,
24,
478
]
]
] |
[
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
],
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
],
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] |
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Carbamazepine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Carbamazepine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Nilotinib (Compound)
Carbamazepine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Carbamazepine may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Carbamazepine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Carbamazepine may lead to a major life threatening interaction when taken with Sonidegib and Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Albendazole and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
|
DB00872
|
DB01129
| 1,080 | 379 |
[
"DDInter438",
"DDInter1559"
] |
Conivaptan
|
Rabeprazole
|
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
|
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
|
Moderate
| 1 |
[
[
[
1080,
24,
379
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
379
]
],
[
[
1080,
21,
28762
],
[
28762,
60,
379
]
],
[
[
1080,
25,
1468
],
[
1468,
62,
379
]
],
[
[
1080,
25,
1476
],
[
1476,
63,
379
]
],
[
[
1080,
63,
883
],
[
883,
24,
379
]
],
[
[
1080,
62,
126
],
[
126,
24,
379
]
],
[
[
1080,
24,
129
],
[
129,
63,
379
]
],
[
[
1080,
25,
1406
],
[
1406,
64,
379
]
],
[
[
1080,
63,
1195
],
[
1195,
25,
379
]
]
] |
[
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rabeprazole"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rabeprazole"
]
]
] |
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rabeprazole (Compound)
Conivaptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Rabeprazole (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Rabeprazole
Conivaptan may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
Conivaptan may lead to a major life threatening interaction when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Rabeprazole
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may lead to a major life threatening interaction when taken with Rabeprazole
|
DB00238
|
DB08882
| 188 | 1,281 |
[
"DDInter1285",
"DDInter1070"
] |
Nevirapine
|
Linagliptin
|
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
|
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
|
Moderate
| 1 |
[
[
[
188,
24,
1281
]
],
[
[
188,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
188,
21,
29081
],
[
29081,
60,
1281
]
],
[
[
188,
24,
251
],
[
251,
24,
1281
]
],
[
[
188,
24,
1320
],
[
1320,
63,
1281
]
],
[
[
188,
63,
1560
],
[
1560,
24,
1281
]
],
[
[
188,
25,
1019
],
[
1019,
63,
1281
]
],
[
[
188,
62,
168
],
[
168,
24,
1281
]
],
[
[
188,
23,
1101
],
[
1101,
25,
1281
]
],
[
[
188,
6,
8374
],
[
8374,
45,
1002
],
[
1002,
1,
1281
]
]
] |
[
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linagliptin"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alogliptin"
],
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
]
]
] |
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Nevirapine (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Linagliptin (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Nevirapine may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Linagliptin
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound) and Alogliptin (Compound) resembles Linagliptin (Compound)
|
DB01069
|
DB09472
| 401 | 1,383 |
[
"DDInter1533",
"DDInter1693"
] |
Promethazine
|
Sodium sulfate
|
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
|
Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions.
|
Moderate
| 1 |
[
[
[
401,
24,
1383
]
],
[
[
401,
24,
609
],
[
609,
24,
1383
]
],
[
[
401,
63,
146
],
[
146,
24,
1383
]
],
[
[
401,
25,
1311
],
[
1311,
24,
1383
]
],
[
[
401,
24,
1612
],
[
1612,
63,
1383
]
],
[
[
401,
74,
1178
],
[
1178,
24,
1383
]
],
[
[
401,
25,
982
],
[
982,
63,
1383
]
],
[
[
401,
64,
675
],
[
675,
24,
1383
]
],
[
[
401,
25,
540
],
[
540,
25,
1383
]
],
[
[
401,
63,
1181
],
[
1181,
25,
1383
]
]
] |
[
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
]
] |
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine (Compound) resembles Trifluoperazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Promethazine may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Sodium sulfate
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may lead to a major life threatening interaction when taken with Sodium sulfate
|
DB00687
|
DB08904
| 870 | 375 |
[
"DDInter747",
"DDInter342"
] |
Fludrocortisone
|
Certolizumab pegol
|
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
|
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
|
Major
| 2 |
[
[
[
870,
25,
375
]
],
[
[
870,
24,
200
],
[
200,
63,
375
]
],
[
[
870,
63,
66
],
[
66,
24,
375
]
],
[
[
870,
24,
409
],
[
409,
24,
375
]
],
[
[
870,
1,
303
],
[
303,
24,
375
]
],
[
[
870,
25,
33
],
[
33,
24,
375
]
],
[
[
870,
23,
1072
],
[
1072,
24,
375
]
],
[
[
870,
64,
1066
],
[
1066,
25,
375
]
],
[
[
870,
25,
1624
],
[
1624,
64,
375
]
],
[
[
870,
1,
1486
],
[
1486,
25,
375
]
]
] |
[
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] |
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fludrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fludrocortisone may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fludrocortisone may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Fludrocortisone may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol
Fludrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may lead to a major life threatening interaction when taken with Certolizumab pegol
|
DB00436
|
DB01142
| 323 | 1,264 |
[
"DDInter179",
"DDInter593"
] |
Bendroflumethiazide
|
Doxepin
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
|
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.
|
Moderate
| 1 |
[
[
[
323,
24,
1264
]
],
[
[
323,
24,
401
],
[
401,
24,
1264
]
],
[
[
323,
21,
28898
],
[
28898,
60,
1264
]
],
[
[
323,
40,
504
],
[
504,
24,
1264
]
],
[
[
323,
24,
659
],
[
659,
63,
1264
]
],
[
[
323,
62,
352
],
[
352,
24,
1264
]
],
[
[
323,
23,
1442
],
[
1442,
24,
1264
]
],
[
[
323,
63,
1648
],
[
1648,
24,
1264
]
],
[
[
323,
40,
178
],
[
178,
63,
1264
]
],
[
[
323,
23,
1511
],
[
1511,
63,
1264
]
]
] |
[
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
]
] |
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Doxepin (Compound)
Bendroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
|
DB00262
|
DB08904
| 552 | 375 |
[
"DDInter302",
"DDInter342"
] |
Carmustine
|
Certolizumab pegol
|
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
|
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
|
Major
| 2 |
[
[
[
552,
25,
375
]
],
[
[
552,
63,
1461
],
[
1461,
23,
375
]
],
[
[
552,
24,
200
],
[
200,
63,
375
]
],
[
[
552,
63,
66
],
[
66,
24,
375
]
],
[
[
552,
24,
208
],
[
208,
24,
375
]
],
[
[
552,
64,
1066
],
[
1066,
25,
375
]
],
[
[
552,
24,
328
],
[
328,
25,
375
]
],
[
[
552,
24,
1330
],
[
1330,
64,
375
]
],
[
[
552,
25,
1624
],
[
1624,
64,
375
]
],
[
[
552,
35,
37
],
[
37,
25,
375
]
]
] |
[
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
],
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Carmustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] |
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin and Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Carmustine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may lead to a major life threatening interaction when taken with Certolizumab pegol
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Certolizumab pegol
Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol
Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may lead to a major life threatening interaction when taken with Certolizumab pegol
|
DB00543
|
DB08899
| 87 | 129 |
[
"DDInter82",
"DDInter649"
] |
Amoxapine
|
Enzalutamide
|
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block
|
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
|
Moderate
| 1 |
[
[
[
87,
24,
129
]
],
[
[
87,
24,
918
],
[
918,
1,
129
]
],
[
[
87,
6,
12523
],
[
12523,
45,
129
]
],
[
[
87,
21,
28703
],
[
28703,
60,
129
]
],
[
[
87,
23,
112
],
[
112,
23,
129
]
],
[
[
87,
63,
79
],
[
79,
24,
129
]
],
[
[
87,
24,
1148
],
[
1148,
24,
129
]
],
[
[
87,
24,
659
],
[
659,
63,
129
]
],
[
[
87,
25,
1133
],
[
1133,
24,
129
]
],
[
[
87,
40,
867
],
[
867,
24,
129
]
]
] |
[
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] |
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Amoxapine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Amoxapine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Amoxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
|
DB00975
|
DB06209
| 1,317 | 256 |
[
"DDInter573",
"DDInter1508"
] |
Dipyridamole
|
Prasugrel
|
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
|
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
|
Major
| 2 |
[
[
[
1317,
25,
256
]
],
[
[
1317,
54,
19166
],
[
19166,
15,
256
]
],
[
[
1317,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1317,
23,
944
],
[
944,
62,
256
]
],
[
[
1317,
24,
901
],
[
901,
24,
256
]
],
[
[
1317,
24,
1427
],
[
1427,
63,
256
]
],
[
[
1317,
63,
305
],
[
305,
24,
256
]
],
[
[
1317,
25,
365
],
[
365,
64,
256
]
],
[
[
1317,
25,
1046
],
[
1046,
25,
256
]
],
[
[
1317,
63,
886
],
[
886,
25,
256
]
]
] |
[
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Decreased Platelet Aggregation"
],
[
"Decreased Platelet Aggregation",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
]
] |
Dipyridamole (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class) and Decreased Platelet Aggregation (Pharmacologic Class) includes Prasugrel (Compound)
Dipyridamole (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Dipyridamole may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Dipyridamole may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Prasugrel
Dipyridamole may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Prasugrel
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Prasugrel
|
DB01039
|
DB08880
| 535 | 1,510 |
[
"DDInter718",
"DDInter1771"
] |
Fenofibrate
|
Teriflunomide
|
Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.
|
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
|
Major
| 2 |
[
[
[
535,
25,
1510
]
],
[
[
535,
63,
1144
],
[
1144,
24,
1510
]
],
[
[
535,
64,
126
],
[
126,
24,
1510
]
],
[
[
535,
63,
1512
],
[
1512,
25,
1510
]
],
[
[
535,
24,
850
],
[
850,
25,
1510
]
],
[
[
535,
24,
283
],
[
283,
64,
1510
]
],
[
[
535,
25,
1377
],
[
1377,
25,
1510
]
],
[
[
535,
64,
467
],
[
467,
25,
1510
]
],
[
[
535,
40,
831
],
[
831,
25,
1510
]
],
[
[
535,
63,
1144
],
[
1144,
24,
129
],
[
129,
63,
1510
]
]
] |
[
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} (Compound) resembles {v} (Compound)",
"Indomethacin"
],
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
]
] |
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Fenofibrate may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Teriflunomide
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Teriflunomide
Fenofibrate may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Teriflunomide
Fenofibrate may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Teriflunomide
Fenofibrate (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Teriflunomide
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
|
DB00286
|
DB00620
| 380 | 175 |
[
"DDInter439",
"DDInter1855"
] |
Conjugated estrogens
|
Triamcinolone
|
The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.[L5605, T475] The conjugated estrogen product contains a mix of estrogen from which about 50% is represented by estrone sulfate followed by 25% of equilin sulfate, 15% of 17-alpha-dehydroequilenin sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate. It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained
|
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.
|
Moderate
| 1 |
[
[
[
380,
24,
175
]
],
[
[
380,
24,
1573
],
[
1573,
1,
175
]
],
[
[
380,
24,
617
],
[
617,
40,
175
]
],
[
[
380,
6,
8374
],
[
8374,
45,
175
]
],
[
[
380,
21,
28661
],
[
28661,
60,
175
]
],
[
[
380,
23,
771
],
[
771,
62,
175
]
],
[
[
380,
24,
1017
],
[
1017,
63,
175
]
],
[
[
380,
63,
1685
],
[
1685,
24,
175
]
],
[
[
380,
40,
1438
],
[
1438,
63,
175
]
],
[
[
380,
24,
1645
],
[
1645,
24,
175
]
]
] |
[
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) causes {v} (Side Effect)",
"Acute coronary syndrome"
],
[
"Acute coronary syndrome",
"{u} (Side Effect) is caused by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
]
] |
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compound)
Conjugated estrogens (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Triamcinolone (Compound)
Conjugated estrogens (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Triamcinolone (Compound)
Conjugated estrogens may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Triamcinolone
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Conjugated estrogens (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
|
DB00215
|
DB09075
| 1,230 | 498 |
[
"DDInter388",
"DDInter621"
] |
Citalopram
|
Edoxaban
|
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
|
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
|
Moderate
| 1 |
[
[
[
1230,
24,
498
]
],
[
[
1230,
25,
222
],
[
222,
24,
498
]
],
[
[
1230,
24,
1017
],
[
1017,
63,
498
]
],
[
[
1230,
1,
318
],
[
318,
24,
498
]
],
[
[
1230,
25,
124
],
[
124,
63,
498
]
],
[
[
1230,
63,
582
],
[
582,
25,
498
]
],
[
[
1230,
24,
714
],
[
714,
25,
498
]
],
[
[
1230,
25,
1213
],
[
1213,
25,
498
]
],
[
[
1230,
25,
283
],
[
283,
64,
498
]
],
[
[
1230,
64,
1018
],
[
1018,
25,
498
]
]
] |
[
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
]
] |
Citalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Citalopram (Compound) resembles Escitalopram (Compound) and Es
Citalopram may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Edoxaban
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Edoxaban
Citalopram may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Citalopram may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Edoxaban
Citalopram may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Edoxaban
|
DB00261
|
DB06754
| 702 | 707 |
[
"DDInter93",
"DDInter471"
] |
Anagrelide
|
Danaparoid
|
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
|
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously.
|
Major
| 2 |
[
[
[
702,
25,
707
]
],
[
[
702,
23,
944
],
[
944,
62,
707
]
],
[
[
702,
24,
1496
],
[
1496,
63,
707
]
],
[
[
702,
24,
901
],
[
901,
24,
707
]
],
[
[
702,
25,
1100
],
[
1100,
24,
707
]
],
[
[
702,
64,
1230
],
[
1230,
24,
707
]
],
[
[
702,
63,
529
],
[
529,
24,
707
]
],
[
[
702,
25,
235
],
[
235,
64,
707
]
],
[
[
702,
64,
1172
],
[
1172,
25,
707
]
],
[
[
702,
25,
291
],
[
291,
25,
707
]
]
] |
[
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
]
] |
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Anagrelide may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Anagrelide may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Anagrelide may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Danaparoid
Anagrelide may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Danaparoid
Anagrelide may lead to a major life threatening interaction when taken with Argatroban and Argatroban may lead to a major life threatening interaction when taken with Danaparoid
|
DB00747
|
DB01193
| 1,442 | 819 |
[
"DDInter1647",
"DDInter12"
] |
Scopolamine
|
Acebutolol
|
Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423,
|
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
|
Moderate
| 1 |
[
[
[
1442,
24,
819
]
],
[
[
1442,
24,
887
],
[
887,
1,
819
]
],
[
[
1442,
63,
1121
],
[
1121,
1,
819
]
],
[
[
1442,
6,
4973
],
[
4973,
45,
819
]
],
[
[
1442,
21,
28762
],
[
28762,
60,
819
]
],
[
[
1442,
24,
1511
],
[
1511,
63,
819
]
],
[
[
1442,
74,
85
],
[
85,
24,
819
]
],
[
[
1442,
63,
1636
],
[
1636,
24,
819
]
],
[
[
1442,
24,
1528
],
[
1528,
24,
819
]
],
[
[
1442,
24,
887
],
[
887,
1,
11529
],
[
11529,
1,
819
]
]
] |
[
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
],
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
]
]
] |
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol (Compound)
Scopolamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Acebutolol (Compound)
Scopolamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Acebutolol (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Oxprenolol (Compound) and Oxprenolol (Compound) resembles Acebutolol (Compound)
|
DB00468
|
DB01138
| 1,424 | 804 |
[
"DDInter1557",
"DDInter1726"
] |
Quinine
|
Sulfinpyrazone
|
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
|
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
|
Moderate
| 1 |
[
[
[
1424,
24,
804
]
],
[
[
1424,
24,
998
],
[
998,
1,
804
]
],
[
[
1424,
6,
3486
],
[
3486,
45,
804
]
],
[
[
1424,
63,
1031
],
[
1031,
23,
804
]
],
[
[
1424,
24,
1144
],
[
1144,
23,
804
]
],
[
[
1424,
24,
629
],
[
629,
24,
804
]
],
[
[
1424,
63,
245
],
[
245,
24,
804
]
],
[
[
1424,
24,
1476
],
[
1476,
63,
804
]
],
[
[
1424,
25,
11
],
[
11,
24,
804
]
],
[
[
1424,
25,
1456
],
[
1456,
63,
804
]
]
] |
[
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
]
] |
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Quinine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfinpyrazone (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Quinine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Quinine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
|
DB00738
|
DB14881
| 485 | 180 |
[
"DDInter1420",
"DDInter1329"
] |
Pentamidine
|
Oliceridine
|
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
|
Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.
|
Moderate
| 1 |
[
[
[
485,
24,
180
]
],
[
[
485,
23,
112
],
[
112,
23,
180
]
],
[
[
485,
24,
401
],
[
401,
24,
180
]
],
[
[
485,
63,
618
],
[
618,
24,
180
]
],
[
[
485,
25,
629
],
[
629,
24,
180
]
],
[
[
485,
64,
1101
],
[
1101,
24,
180
]
],
[
[
485,
64,
702
],
[
702,
25,
180
]
],
[
[
485,
25,
1154
],
[
1154,
25,
180
]
],
[
[
485,
24,
1133
],
[
1133,
25,
180
]
],
[
[
485,
63,
1494
],
[
1494,
25,
180
]
]
] |
[
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
]
] |
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pentamidine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pentamidine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Pentamidine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Oliceridine
Pentamidine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Oliceridine
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Oliceridine
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Oliceridine
|
DB01088
|
DB08907
| 714 | 1,344 |
[
"DDInter908",
"DDInter280"
] |
Iloprost
|
Canagliflozin
|
Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties.
|
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
|
Moderate
| 1 |
[
[
[
714,
24,
1344
]
],
[
[
714,
24,
549
],
[
549,
1,
1344
]
],
[
[
714,
63,
1445
],
[
1445,
24,
1344
]
],
[
[
714,
24,
1549
],
[
1549,
24,
1344
]
],
[
[
714,
24,
947
],
[
947,
63,
1344
]
],
[
[
714,
25,
4
],
[
4,
24,
1344
]
],
[
[
714,
62,
402
],
[
402,
24,
1344
]
],
[
[
714,
24,
549
],
[
549,
6,
16207
],
[
16207,
45,
1344
]
],
[
[
714,
63,
1445
],
[
1445,
24,
549
],
[
549,
1,
1344
]
],
[
[
714,
24,
1549
],
[
1549,
24,
549
],
[
549,
1,
1344
]
]
] |
[
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nesiritide"
],
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
],
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tadalafil"
],
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) binds {v} (Gene)",
"SLC5A1"
],
[
"SLC5A1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nesiritide"
],
[
"Nesiritide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
]
] |
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Nesiritide and Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Riociguat and Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Iloprost may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Iloprost may cause a minor interaction that can limit clinical effects when taken with Tadalafil and Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Nesiritide and Nesiritide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
|
DB00999
|
DB11921
| 504 | 1,019 |
[
"DDInter883",
"DDInter492"
] |
Hydrochlorothiazide
|
Deflazacort
|
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.
|
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
|
Moderate
| 1 |
[
[
[
504,
24,
1019
]
],
[
[
504,
24,
959
],
[
959,
24,
1019
]
],
[
[
504,
1,
1326
],
[
1326,
24,
1019
]
],
[
[
504,
63,
355
],
[
355,
24,
1019
]
],
[
[
504,
24,
1385
],
[
1385,
63,
1019
]
],
[
[
504,
62,
126
],
[
126,
24,
1019
]
],
[
[
504,
40,
178
],
[
178,
24,
1019
]
],
[
[
504,
24,
1220
],
[
1220,
25,
1019
]
],
[
[
504,
62,
600
],
[
600,
25,
1019
]
],
[
[
504,
24,
959
],
[
959,
63,
1072
],
[
1072,
23,
1019
]
]
] |
[
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
]
] |
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Hydrochlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Deflazacort
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
|
DB00851
|
DB01004
| 611 | 563 |
[
"DDInter463",
"DDInter806"
] |
Dacarbazine
|
Ganciclovir
|
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
|
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
|
Moderate
| 1 |
[
[
[
611,
24,
563
]
],
[
[
611,
24,
248
],
[
248,
40,
563
]
],
[
[
611,
63,
552
],
[
552,
24,
563
]
],
[
[
611,
25,
770
],
[
770,
63,
563
]
],
[
[
611,
24,
869
],
[
869,
63,
563
]
],
[
[
611,
24,
1686
],
[
1686,
24,
563
]
],
[
[
611,
64,
1648
],
[
1648,
24,
563
]
],
[
[
611,
25,
375
],
[
375,
64,
563
]
],
[
[
611,
64,
581
],
[
581,
25,
563
]
],
[
[
611,
24,
248
],
[
248,
1,
11809
],
[
11809,
40,
563
]
]
] |
[
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ganciclovir"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Penciclovir"
],
[
"Penciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
]
]
] |
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Dacarbazine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Dacarbazine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ganciclovir
Dacarbazine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Ganciclovir
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Penciclovir (Compound) and Penciclovir (Compound) resembles Ganciclovir (Compound)
|
DB04865
|
DB06081
| 4 | 1,046 |
[
"DDInter1335",
"DDInter286"
] |
Omacetaxine mepesuccinate
|
Caplacizumab
|
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
|
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
|
Major
| 2 |
[
[
[
4,
25,
1046
]
],
[
[
4,
64,
1171
],
[
1171,
24,
1046
]
],
[
[
4,
63,
305
],
[
305,
24,
1046
]
],
[
[
4,
24,
637
],
[
637,
63,
1046
]
],
[
[
4,
64,
1479
],
[
1479,
25,
1046
]
],
[
[
4,
25,
256
],
[
256,
64,
1046
]
],
[
[
4,
63,
1213
],
[
1213,
25,
1046
]
],
[
[
4,
24,
39
],
[
39,
64,
1046
]
],
[
[
4,
25,
1564
],
[
1564,
25,
1046
]
],
[
[
4,
64,
1171
],
[
1171,
24,
1039
],
[
1039,
24,
1046
]
]
] |
[
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
]
] |
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Caplacizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Caplacizumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Caplacizumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Caplacizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Caplacizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
|
DB06589
|
DB15233
| 1,250 | 1,650 |
[
"DDInter1400",
"DDInter142"
] |
Pazopanib
|
Avapritinib
|
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
|
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020.
|
Moderate
| 1 |
[
[
[
1250,
24,
1650
]
],
[
[
1250,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
1250,
63,
1374
],
[
1374,
24,
1650
]
],
[
[
1250,
25,
982
],
[
982,
24,
1650
]
],
[
[
1250,
64,
478
],
[
478,
24,
1650
]
],
[
[
1250,
25,
908
],
[
908,
25,
1650
]
],
[
[
1250,
63,
4
],
[
4,
25,
1650
]
],
[
[
1250,
64,
1377
],
[
1377,
25,
1650
]
],
[
[
1250,
24,
913
],
[
913,
25,
1650
]
],
[
[
1250,
24,
1478
],
[
1478,
63,
1374
],
[
1374,
24,
1650
]
]
] |
[
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
]
] |
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Pazopanib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Pazopanib may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Avapritinib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib
Pazopanib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Avapritinib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Avapritinib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
|
DB01177
|
DB12161
| 77 | 730 |
[
"DDInter904",
"DDInter512"
] |
Idarubicin
|
Deutetrabenazine
|
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
|
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.
|
Moderate
| 1 |
[
[
[
77,
24,
730
]
],
[
[
77,
62,
112
],
[
112,
23,
730
]
],
[
[
77,
74,
322
],
[
322,
24,
730
]
],
[
[
77,
63,
1559
],
[
1559,
24,
730
]
],
[
[
77,
24,
971
],
[
971,
24,
730
]
],
[
[
77,
64,
770
],
[
770,
24,
730
]
],
[
[
77,
24,
1619
],
[
1619,
63,
730
]
],
[
[
77,
64,
11
],
[
11,
25,
730
]
],
[
[
77,
25,
877
],
[
877,
64,
730
]
],
[
[
77,
25,
1487
],
[
1487,
25,
730
]
]
] |
[
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
]
] |
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Idarubicin (Compound) resembles Epirubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Idarubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Idarubicin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Deutetrabenazine
Idarubicin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Deutetrabenazine
Idarubicin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Deutetrabenazine
|
DB00975
|
DB03404
| 1,317 | 765 |
[
"DDInter573",
"DDInter855"
] |
Dipyridamole
|
Hemin
|
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
|
Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
|
Moderate
| 1 |
[
[
[
1317,
24,
765
]
],
[
[
1317,
25,
840
],
[
840,
63,
765
]
],
[
[
1317,
64,
291
],
[
291,
24,
765
]
],
[
[
1317,
63,
1061
],
[
1061,
24,
765
]
],
[
[
1317,
24,
1496
],
[
1496,
63,
765
]
],
[
[
1317,
24,
714
],
[
714,
24,
765
]
],
[
[
1317,
25,
500
],
[
500,
24,
765
]
],
[
[
1317,
25,
840
],
[
840,
64,
291
],
[
291,
24,
765
]
],
[
[
1317,
64,
291
],
[
291,
25,
840
],
[
840,
63,
765
]
],
[
[
1317,
63,
1061
],
[
1061,
24,
840
],
[
840,
63,
765
]
]
] |
[
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
]
] |
Dipyridamole may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may lead to a major life threatening interaction when taken with Argatroban and Argatroban may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
|
DB01216
|
DB01404
| 284 | 757 |
[
"DDInter736",
"DDInter820"
] |
Finasteride
|
Ginseng
|
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperpl
|
Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens.
|
Moderate
| 1 |
[
[
[
284,
24,
757
]
],
[
[
284,
21,
28921
],
[
28921,
60,
245
],
[
245,
24,
757
]
],
[
[
284,
21,
28921
],
[
28921,
60,
578
],
[
578,
63,
757
]
],
[
[
284,
21,
29462
],
[
29462,
60,
1419
],
[
1419,
25,
757
]
],
[
[
284,
63,
798
],
[
798,
24,
245
],
[
245,
24,
757
]
],
[
[
284,
24,
1327
],
[
1327,
63,
245
],
[
245,
24,
757
]
],
[
[
284,
1,
1561
],
[
1561,
63,
245
],
[
245,
24,
757
]
],
[
[
284,
63,
798
],
[
798,
25,
578
],
[
578,
63,
757
]
],
[
[
284,
40,
1260
],
[
1260,
63,
1419
],
[
1419,
25,
757
]
],
[
[
284,
24,
1327
],
[
1327,
25,
578
],
[
578,
63,
757
]
]
] |
[
[
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} (Compound) resembles {v} (Compound)",
"Dutasteride"
],
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ginseng"
]
],
[
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
]
] |
Finasteride (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Finasteride (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Finasteride (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Ginseng
Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Finasteride (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Finasteride (Compound) resembles Dutasteride (Compound) and Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Ginseng
Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
|
DB00794
|
DB03404
| 759 | 765 |
[
"DDInter1521",
"DDInter855"
] |
Primidone
|
Hemin
|
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
|
Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
|
Major
| 2 |
[
[
[
759,
25,
765
]
],
[
[
759,
25,
840
],
[
840,
63,
765
]
],
[
[
759,
24,
1421
],
[
1421,
63,
765
]
],
[
[
759,
64,
126
],
[
126,
24,
765
]
],
[
[
759,
25,
1213
],
[
1213,
24,
765
]
],
[
[
759,
1,
697
],
[
697,
25,
765
]
],
[
[
759,
25,
840
],
[
840,
64,
291
],
[
291,
24,
765
]
],
[
[
759,
25,
1496
],
[
1496,
63,
840
],
[
840,
63,
765
]
],
[
[
759,
25,
578
],
[
578,
24,
840
],
[
840,
63,
765
]
],
[
[
759,
25,
1409
],
[
1409,
25,
840
],
[
840,
63,
765
]
]
] |
[
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
]
] |
Primidone may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Hemin
Primidone may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone may lead to a major life threatening interaction when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Primidone may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
|
DB00250
|
DB00855
| 10 | 213 |
[
"DDInter475",
"DDInter72"
] |
Dapsone
|
Aminolevulinic acid
|
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
|
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
|
Major
| 2 |
[
[
[
10,
25,
213
]
],
[
[
10,
21,
29966
],
[
29966,
60,
213
]
],
[
[
10,
24,
1040
],
[
1040,
64,
213
]
],
[
[
10,
24,
1419
],
[
1419,
25,
213
]
],
[
[
10,
1,
1247
],
[
1247,
64,
213
]
],
[
[
10,
35,
161
],
[
161,
25,
213
]
],
[
[
10,
21,
29966
],
[
29966,
60,
11546
],
[
11546,
40,
213
]
],
[
[
10,
21,
28722
],
[
28722,
60,
191
],
[
191,
1,
213
]
],
[
[
10,
24,
1040
],
[
1040,
7,
18134
],
[
18134,
46,
213
]
],
[
[
10,
1,
1247
],
[
1247,
21,
28722
],
[
28722,
60,
213
]
]
] |
[
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Application site reaction"
],
[
"Application site reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Application site reaction"
],
[
"Application site reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azelaic Acid"
],
[
"Azelaic Acid",
"{u} (Compound) resembles {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminocaproic acid"
],
[
"Aminocaproic acid",
"{u} (Compound) resembles {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} (Compound) upregulates {v} (Gene)",
"POLD4"
],
[
"POLD4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Dapsone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminolevulinic acid"
]
]
] |
Dapsone (Compound) causes Application site reaction (Side Effect) and Application site reaction (Side Effect) is caused by Aminolevulinic acid (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Aminolevulinic acid
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Aminolevulinic acid
Dapsone (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may lead to a major life threatening interaction when taken with Aminolevulinic acid
Dapsone (Compound) resembles Sulfadiazine (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine may lead to a major life threatening interaction when taken with Aminolevulinic acid
Dapsone (Compound) causes Application site reaction (Side Effect) and Application site reaction (Side Effect) is caused by Azelaic Acid (Compound) and Azelaic Acid (Compound) resembles Aminolevulinic acid (Compound)
Dapsone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Aminocaproic acid (Compound) and Aminocaproic acid (Compound) resembles Aminolevulinic acid (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Aminolevulinic acid (Compound)
Dapsone (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Aminolevulinic acid (Compound)
|
DB01175
|
DB03904
| 318 | 1,574 |
[
"DDInter672",
"DDInter1903"
] |
Escitalopram
|
Urea
|
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
|
A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
|
Moderate
| 1 |
[
[
[
318,
24,
1574
]
],
[
[
318,
63,
1314
],
[
1314,
24,
1574
]
],
[
[
318,
40,
1230
],
[
1230,
24,
1574
]
],
[
[
318,
24,
657
],
[
657,
63,
1574
]
],
[
[
318,
25,
497
],
[
497,
24,
1574
]
],
[
[
318,
64,
222
],
[
222,
24,
1574
]
],
[
[
318,
63,
1314
],
[
1314,
24,
643
],
[
643,
63,
1574
]
],
[
[
318,
40,
1230
],
[
1230,
63,
1314
],
[
1314,
24,
1574
]
],
[
[
318,
24,
657
],
[
657,
63,
1230
],
[
1230,
24,
1574
]
],
[
[
318,
25,
497
],
[
497,
25,
1399
],
[
1399,
62,
1574
]
]
] |
[
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} (Compound) resembles {v} (Compound)",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} (Compound) resembles {v} (Compound)",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Urea"
]
]
] |
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram (Compound) resembles Citalopram (Compound) and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram (Compound) resembles Citalopram (Compound) and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Urea
Escitalopram may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Urea
|
DB00976
|
DB11110
| 1,056 | 603 |
[
"DDInter1758",
"DDInter1115"
] |
Telithromycin
|
Magnesium citrate
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
|
Moderate
| 1 |
[
[
[
1056,
24,
603
]
],
[
[
1056,
25,
57
],
[
57,
24,
603
]
],
[
[
1056,
24,
1616
],
[
1616,
24,
603
]
],
[
[
1056,
63,
870
],
[
870,
24,
603
]
],
[
[
1056,
25,
484
],
[
484,
63,
603
]
],
[
[
1056,
64,
1424
],
[
1424,
24,
603
]
],
[
[
1056,
1,
1570
],
[
1570,
24,
603
]
],
[
[
1056,
35,
609
],
[
609,
24,
603
]
],
[
[
1056,
24,
823
],
[
823,
63,
603
]
],
[
[
1056,
25,
57
],
[
57,
64,
789
],
[
789,
24,
603
]
]
] |
[
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] |
Telithromycin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin (Compound) resembles Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Telithromycin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
|
DB00182
|
DB00938
| 80 | 455 |
[
"DDInter84",
"DDInter1635"
] |
Amphetamine
|
Salmeterol
|
Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976. During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit
|
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
|
Moderate
| 1 |
[
[
[
80,
24,
455
]
],
[
[
80,
24,
688
],
[
688,
63,
455
]
],
[
[
80,
21,
29024
],
[
29024,
60,
455
]
],
[
[
80,
40,
1144
],
[
1144,
24,
455
]
],
[
[
80,
24,
874
],
[
874,
24,
455
]
],
[
[
80,
25,
222
],
[
222,
63,
455
]
],
[
[
80,
40,
633
],
[
633,
63,
455
]
],
[
[
80,
25,
121
],
[
121,
24,
455
]
],
[
[
80,
25,
290
],
[
290,
25,
455
]
],
[
[
80,
24,
760
],
[
760,
64,
455
]
]
] |
[
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
]
] |
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amphetamine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Salmeterol (Compound)
Amphetamine (Compound) resembles Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amphetamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amphetamine (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amphetamine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amphetamine may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Salmeterol
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Salmeterol
|
DB11901
|
DB12825
| 913 | 1,375 |
[
"DDInter107",
"DDInter1032"
] |
Apalutamide
|
Lefamulin
|
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing
|
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
|
Major
| 2 |
[
[
[
913,
25,
1375
]
],
[
[
913,
62,
112
],
[
112,
23,
1375
]
],
[
[
913,
25,
159
],
[
159,
63,
1375
]
],
[
[
913,
63,
1532
],
[
1532,
24,
1375
]
],
[
[
913,
64,
976
],
[
976,
24,
1375
]
],
[
[
913,
24,
1320
],
[
1320,
24,
1375
]
],
[
[
913,
25,
1019
],
[
1019,
24,
1375
]
],
[
[
913,
62,
608
],
[
608,
24,
1375
]
],
[
[
913,
64,
1069
],
[
1069,
25,
1375
]
],
[
[
913,
63,
1494
],
[
1494,
25,
1375
]
]
] |
[
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
] |
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Apalutamide may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apalutamide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apalutamide may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apalutamide may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lefamulin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Lefamulin
|
DB00022
|
DB00515
| 268 | 589 |
[
"DDInter1408",
"DDInter387"
] |
Peginterferon alfa-2b
|
Cisplatin
|
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
|
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
|
Moderate
| 1 |
[
[
[
268,
24,
589
]
],
[
[
268,
24,
1468
],
[
1468,
63,
589
]
],
[
[
268,
24,
367
],
[
367,
24,
589
]
],
[
[
268,
25,
1477
],
[
1477,
63,
589
]
],
[
[
268,
63,
1451
],
[
1451,
24,
589
]
],
[
[
268,
23,
450
],
[
450,
63,
589
]
],
[
[
268,
25,
139
],
[
139,
24,
589
]
],
[
[
268,
25,
1292
],
[
1292,
64,
589
]
],
[
[
268,
24,
1568
],
[
1568,
64,
589
]
],
[
[
268,
25,
1064
],
[
1064,
25,
589
]
]
] |
[
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
]
] |
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Cisplatin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Cisplatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Cisplatin
|
DB01138
|
DB09049
| 804 | 1,135 |
[
"DDInter1726",
"DDInter1261"
] |
Sulfinpyrazone
|
Naloxegol
|
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
|
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
|
Moderate
| 1 |
[
[
[
804,
24,
1135
]
],
[
[
804,
24,
971
],
[
971,
62,
1135
]
],
[
[
804,
63,
1424
],
[
1424,
23,
1135
]
],
[
[
804,
24,
478
],
[
478,
23,
1135
]
],
[
[
804,
25,
1618
],
[
1618,
23,
1135
]
],
[
[
804,
40,
998
],
[
998,
24,
1135
]
],
[
[
804,
62,
1101
],
[
1101,
24,
1135
]
],
[
[
804,
24,
927
],
[
927,
63,
1135
]
],
[
[
804,
63,
1419
],
[
1419,
25,
1135
]
],
[
[
804,
24,
384
],
[
384,
64,
1135
]
]
] |
[
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
]
] |
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sulfinpyrazone may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Naloxegol
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Naloxegol
|
DB01211
|
DB12887
| 609 | 1,598 |
[
"DDInter393",
"DDInter1750"
] |
Clarithromycin
|
Tazemetostat
|
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
|
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
|
Major
| 2 |
[
[
[
609,
25,
1598
]
],
[
[
609,
63,
168
],
[
168,
23,
1598
]
],
[
[
609,
25,
594
],
[
594,
24,
1598
]
],
[
[
609,
24,
310
],
[
310,
24,
1598
]
],
[
[
609,
64,
134
],
[
134,
24,
1598
]
],
[
[
609,
63,
888
],
[
888,
24,
1598
]
],
[
[
609,
62,
752
],
[
752,
24,
1598
]
],
[
[
609,
24,
466
],
[
466,
63,
1598
]
],
[
[
609,
25,
982
],
[
982,
63,
1598
]
],
[
[
609,
24,
913
],
[
913,
25,
1598
]
]
] |
[
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
]
]
] |
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Clarithromycin may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Tazemetostat
|
DB00026
|
DB09389
| 1,184 | 517 |
[
"DDInter94",
"DDInter1315"
] |
Anakinra
|
Norgestrel
|
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
|
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
|
Moderate
| 1 |
[
[
[
1184,
24,
517
]
],
[
[
1184,
25,
581
],
[
581,
24,
517
]
],
[
[
1184,
24,
1213
],
[
1213,
24,
517
]
],
[
[
1184,
64,
1057
],
[
1057,
24,
517
]
],
[
[
1184,
63,
305
],
[
305,
24,
517
]
],
[
[
1184,
25,
1583
],
[
1583,
63,
517
]
],
[
[
1184,
24,
1093
],
[
1093,
63,
517
]
],
[
[
1184,
24,
350
],
[
350,
25,
517
]
],
[
[
1184,
24,
1476
],
[
1476,
64,
517
]
],
[
[
1184,
25,
581
],
[
581,
24,
14
],
[
14,
23,
517
]
]
] |
[
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
]
] |
Anakinra may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Anakinra may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Norgestrel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Norgestrel
Anakinra may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
|
DB00366
|
DB00494
| 1,594 | 1,533 |
[
"DDInter600",
"DDInter646"
] |
Doxylamine
|
Entacapone
|
Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
|
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.
|
Moderate
| 1 |
[
[
[
1594,
24,
1533
]
],
[
[
1594,
63,
1062
],
[
1062,
1,
1533
]
],
[
[
1594,
21,
28769
],
[
28769,
60,
1533
]
],
[
[
1594,
24,
770
],
[
770,
63,
1533
]
],
[
[
1594,
35,
128
],
[
128,
24,
1533
]
],
[
[
1594,
74,
701
],
[
701,
24,
1533
]
],
[
[
1594,
24,
530
],
[
530,
24,
1533
]
],
[
[
1594,
63,
475
],
[
475,
24,
1533
]
],
[
[
1594,
35,
272
],
[
272,
63,
1533
]
],
[
[
1594,
25,
1629
],
[
1629,
64,
1533
]
]
] |
[
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} (Compound) resembles {v} (Compound)",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entacapone"
]
]
] |
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Doxylamine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Entacapone (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Doxylamine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Entacapone
|
DB01075
|
DB11186
| 1,376 | 1,609 |
[
"DDInter569",
"DDInter1427"
] |
Diphenhydramine
|
Pentoxyverine
|
Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed
|
Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed.
|
Moderate
| 1 |
[
[
[
1376,
24,
1609
]
],
[
[
1376,
63,
314
],
[
314,
24,
1609
]
],
[
[
1376,
64,
306
],
[
306,
24,
1609
]
],
[
[
1376,
24,
716
],
[
716,
24,
1609
]
],
[
[
1376,
24,
418
],
[
418,
63,
1609
]
],
[
[
1376,
74,
21
],
[
21,
24,
1609
]
],
[
[
1376,
35,
1264
],
[
1264,
24,
1609
]
],
[
[
1376,
36,
1301
],
[
1301,
24,
1609
]
],
[
[
1376,
25,
1241
],
[
1241,
24,
1609
]
],
[
[
1376,
24,
1163
],
[
1163,
25,
1609
]
]
] |
[
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
],
[
"Dantrolene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
],
[
"Brexanolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentoxyverine"
]
]
] |
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene and Dantrolene may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone and Brexanolone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine (Compound) resembles Amitriptyline (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine (Compound) resembles Levacetylmethadol (Compound) and Diphenhydramine may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine may lead to a major life threatening interaction when taken with Brexpiprazole and Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline and Rasagiline may lead to a major life threatening interaction when taken with Pentoxyverine
|
DB00981
|
DB01210
| 1,528 | 668 |
[
"DDInter1462",
"DDInter1050"
] |
Physostigmine
|
Levobunolol (ophthalmic)
|
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
|
Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin.
|
Moderate
| 1 |
[
[
[
1528,
24,
668
]
],
[
[
1528,
63,
461
],
[
461,
1,
668
]
],
[
[
1528,
24,
729
],
[
729,
1,
668
]
],
[
[
1528,
24,
699
],
[
699,
40,
668
]
],
[
[
1528,
5,
11595
],
[
11595,
44,
668
]
],
[
[
1528,
21,
28653
],
[
28653,
60,
668
]
],
[
[
1528,
25,
497
],
[
497,
63,
668
]
],
[
[
1528,
24,
1476
],
[
1476,
63,
668
]
],
[
[
1528,
24,
770
],
[
770,
24,
668
]
],
[
[
1528,
63,
461
],
[
461,
25,
688
],
[
688,
25,
668
]
]
] |
[
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} (Compound) treats {v} (Disease)",
"glaucoma"
],
[
"glaucoma",
"{u} (Disease) is treated by {v} (Compound)",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Bradycardia"
],
[
"Bradycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobunolol"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levobunolol"
]
]
] |
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Levobunolol
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Levobunolol (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Levobunolol (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Levobunolol (Compound)
Physostigmine (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Levobunolol (Compound)
Physostigmine (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Levobunolol (Compound)
Physostigmine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Levobunolol
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Levobunolol
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levobunolol
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol may lead to a major life threatening interaction when taken with Levobunolol
|
DB00197
|
DB12141
| 1,324 | 971 |
[
"DDInter1881",
"DDInter817"
] |
Troglitazone
|
Gilteritinib
|
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
|
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
|
Moderate
| 1 |
[
[
[
1324,
24,
971
]
],
[
[
1324,
24,
1135
],
[
1135,
23,
971
]
],
[
[
1324,
24,
466
],
[
466,
62,
971
]
],
[
[
1324,
24,
485
],
[
485,
24,
971
]
],
[
[
1324,
24,
242
],
[
242,
63,
971
]
],
[
[
1324,
23,
1612
],
[
1612,
24,
971
]
],
[
[
1324,
63,
912
],
[
912,
24,
971
]
],
[
[
1324,
24,
540
],
[
540,
25,
971
]
],
[
[
1324,
23,
1101
],
[
1101,
25,
971
]
],
[
[
1324,
25,
1070
],
[
1070,
25,
971
]
]
] |
[
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] |
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Gilteritinib
Troglitazone may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Gilteritinib
|
DB08913
|
DB09073
| 1,186 | 951 |
[
"DDInter1561",
"DDInter1379"
] |
Radium Ra 223 dichloride
|
Palbociclib
|
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
|
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
|
Moderate
| 1 |
[
[
[
1186,
24,
951
]
],
[
[
1186,
63,
134
],
[
134,
24,
951
]
],
[
[
1186,
24,
405
],
[
405,
63,
951
]
],
[
[
1186,
24,
676
],
[
676,
64,
951
]
],
[
[
1186,
63,
1064
],
[
1064,
25,
951
]
],
[
[
1186,
63,
134
],
[
134,
24,
496
],
[
496,
63,
951
]
],
[
[
1186,
24,
405
],
[
405,
63,
318
],
[
318,
23,
951
]
],
[
[
1186,
24,
351
],
[
351,
23,
907
],
[
907,
62,
951
]
],
[
[
1186,
63,
478
],
[
478,
23,
907
],
[
907,
62,
951
]
],
[
[
1186,
63,
1491
],
[
1491,
64,
318
],
[
318,
23,
951
]
]
] |
[
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
]
] |
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
|
DB05239
|
DB12035
| 866 | 943 |
[
"DDInter425",
"DDInter1641"
] |
Cobimetinib
|
Sarecycline
|
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
|
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.
|
Moderate
| 1 |
[
[
[
866,
24,
943
]
],
[
[
866,
63,
842
],
[
842,
24,
943
]
],
[
[
866,
24,
1670
],
[
1670,
24,
943
]
],
[
[
866,
24,
1619
],
[
1619,
63,
943
]
],
[
[
866,
25,
384
],
[
384,
24,
943
]
],
[
[
866,
64,
1419
],
[
1419,
24,
943
]
],
[
[
866,
64,
213
],
[
213,
25,
943
]
],
[
[
866,
63,
842
],
[
842,
24,
392
],
[
392,
24,
943
]
],
[
[
866,
24,
1670
],
[
1670,
23,
1135
],
[
1135,
23,
943
]
],
[
[
866,
24,
850
],
[
850,
24,
1670
],
[
1670,
24,
943
]
]
] |
[
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
]
] |
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Cobimetinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Cobimetinib may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Sarecycline
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
|
DB00393
|
DB08907
| 854 | 1,344 |
[
"DDInter1295",
"DDInter280"
] |
Nimodipine
|
Canagliflozin
|
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
|
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
|
Moderate
| 1 |
[
[
[
854,
24,
1344
]
],
[
[
854,
24,
549
],
[
549,
1,
1344
]
],
[
[
854,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
854,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
854,
1,
1081
],
[
1081,
24,
1344
]
],
[
[
854,
63,
999
],
[
999,
24,
1344
]
],
[
[
854,
24,
98
],
[
98,
63,
1344
]
],
[
[
854,
24,
104
],
[
104,
24,
1344
]
],
[
[
854,
25,
609
],
[
609,
24,
1344
]
],
[
[
854,
24,
549
],
[
549,
6,
16207
],
[
16207,
45,
1344
]
]
] |
[
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) binds {v} (Gene)",
"SLC5A1"
],
[
"SLC5A1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
]
] |
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Nimodipine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
Nimodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nimodipine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
|
DB00175
|
DB00563
| 681 | 663 |
[
"DDInter1509",
"DDInter1174"
] |
Pravastatin
|
Methotrexate
|
Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.
|
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
|
Moderate
| 1 |
[
[
[
681,
24,
663
]
],
[
[
681,
6,
4390
],
[
4390,
45,
663
]
],
[
[
681,
21,
28681
],
[
28681,
60,
663
]
],
[
[
681,
23,
126
],
[
126,
62,
663
]
],
[
[
681,
24,
1487
],
[
1487,
62,
663
]
],
[
[
681,
24,
1501
],
[
1501,
63,
663
]
],
[
[
681,
24,
589
],
[
589,
24,
663
]
],
[
[
681,
63,
1560
],
[
1560,
24,
663
]
],
[
[
681,
1,
1463
],
[
1463,
24,
663
]
],
[
[
681,
25,
1668
],
[
1668,
24,
663
]
]
] |
[
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} (Compound) binds {v} (Gene)",
"SLC16A1"
],
[
"SLC16A1",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound)",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Pravastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
]
] |
Pravastatin (Compound) binds SLC16A1 (Gene) and SLC16A1 (Gene) is bound by Methotrexate (Compound)
Pravastatin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Pravastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Pravastatin (Compound) resembles Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Pravastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
|
DB00215
|
DB06691
| 1,230 | 849 |
[
"DDInter388",
"DDInter1155"
] |
Citalopram
|
Mepyramine
|
Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.
|
Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
|
Moderate
| 1 |
[
[
[
1230,
24,
849
]
],
[
[
1230,
24,
1594
],
[
1594,
24,
849
]
],
[
[
1230,
6,
12523
],
[
12523,
45,
849
]
],
[
[
1230,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1230,
24,
407
],
[
407,
63,
849
]
],
[
[
1230,
25,
401
],
[
401,
24,
849
]
],
[
[
1230,
1,
318
],
[
318,
24,
849
]
],
[
[
1230,
24,
662
],
[
662,
35,
849
]
],
[
[
1230,
24,
1594
],
[
1594,
1,
11775
],
[
11775,
40,
849
]
],
[
[
1230,
6,
12523
],
[
12523,
45,
23
],
[
23,
40,
849
]
]
] |
[
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
]
] |
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Citalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Citalopram may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Citalopram (Compound) resembles Escitalopram (Compound) and Es
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Citalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Mepyramine (Compound)
|
DB00454
|
DB00572
| 1,349 | 85 |
[
"DDInter1150",
"DDInter136"
] |
Meperidine
|
Atropine
|
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
|
Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products.[A251660,L42840] Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters.[A251660,L42815,L42825,L42835] It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.
|
Moderate
| 1 |
[
[
[
1349,
24,
85
]
],
[
[
1349,
40,
11228
],
[
11228,
40,
85
]
],
[
[
1349,
63,
19
],
[
19,
24,
85
]
],
[
[
1349,
25,
1166
],
[
1166,
40,
85
]
],
[
[
1349,
21,
28722
],
[
28722,
60,
85
]
],
[
[
1349,
24,
272
],
[
272,
63,
85
]
],
[
[
1349,
64,
475
],
[
475,
24,
85
]
],
[
[
1349,
25,
1264
],
[
1264,
63,
85
]
],
[
[
1349,
40,
411
],
[
411,
63,
85
]
],
[
[
1349,
24,
1442
],
[
1442,
74,
85
]
]
] |
[
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclopentolate"
],
[
"Cyclopentolate",
"{u} (Compound) resembles {v} (Compound)",
"Atropine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} (Compound) resembles {v} (Compound)",
"Atropine"
]
],
[
[
"Meperidine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atropine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
],
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
]
] |
Meperidine (Compound) resembles Cyclopentolate (Compound) and Cyclopentolate (Compound) resembles Atropine (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Meperidine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron (Compound) resembles Atropine (Compound)
Meperidine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Atropine (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Meperidine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Meperidine (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
|
DB00321
|
DB11963
| 21 | 1,045 |
[
"DDInter78",
"DDInter465"
] |
Amitriptyline
|
Dacomitinib
|
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
|
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.
|
Moderate
| 1 |
[
[
[
21,
24,
1045
]
],
[
[
21,
25,
1039
],
[
1039,
24,
1045
]
],
[
[
21,
35,
1376
],
[
1376,
24,
1045
]
],
[
[
21,
24,
272
],
[
272,
24,
1045
]
],
[
[
21,
40,
1164
],
[
1164,
24,
1045
]
],
[
[
21,
24,
710
],
[
710,
63,
1045
]
],
[
[
21,
1,
1237
],
[
1237,
24,
1045
]
],
[
[
21,
24,
1670
],
[
1670,
25,
1045
]
],
[
[
21,
25,
1039
],
[
1039,
62,
479
],
[
479,
23,
1045
]
],
[
[
21,
35,
1376
],
[
1376,
63,
479
],
[
479,
23,
1045
]
]
] |
[
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacomitinib"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacomitinib"
]
]
] |
Amitriptyline may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Amitriptyline (Compound) resembles Diphenhydramine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Amitriptyline (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Amitriptyline (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Dacomitinib
Amitriptyline may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Amitriptyline (Compound) resembles Diphenhydramine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
|
DB00690
|
DB00877
| 1,216 | 629 |
[
"DDInter762",
"DDInter1678"
] |
Flurazepam
|
Sirolimus
|
A benzodiazepine derivative used mainly as a hypnotic.
|
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
|
Moderate
| 1 |
[
[
[
1216,
24,
629
]
],
[
[
1216,
6,
4973
],
[
4973,
45,
629
]
],
[
[
1216,
21,
29203
],
[
29203,
60,
629
]
],
[
[
1216,
40,
1418
],
[
1418,
63,
629
]
],
[
[
1216,
24,
1311
],
[
1311,
63,
629
]
],
[
[
1216,
63,
752
],
[
752,
24,
629
]
],
[
[
1216,
40,
1382
],
[
1382,
24,
629
]
],
[
[
1216,
1,
902
],
[
902,
24,
629
]
],
[
[
1216,
1,
481
],
[
481,
63,
629
]
],
[
[
1216,
62,
1031
],
[
1031,
24,
629
]
]
] |
[
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Aspartate aminotransferase increased"
],
[
"Aspartate aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Flurazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
]
] |
Flurazepam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Flurazepam (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Flurazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Flurazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Flurazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Flurazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Flurazepam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
|
DB01068
|
DB09154
| 1,565 | 1,475 |
[
"DDInter411",
"DDInter1686"
] |
Clonazepam
|
Sodium citrate
|
A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately
|
Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works by neutralizing excess acid in the blood and urine. It has been indicated for the treatment of metabolic acidosis.
|
Minor
| 0 |
[
[
[
1565,
23,
1475
]
],
[
[
1565,
1,
1563
],
[
1563,
23,
1475
]
],
[
[
1565,
40,
523
],
[
523,
23,
1475
]
],
[
[
1565,
24,
478
],
[
478,
24,
1475
]
],
[
[
1565,
23,
115
],
[
115,
25,
1475
]
],
[
[
1565,
1,
1563
],
[
1563,
1,
902
],
[
902,
23,
1475
]
],
[
[
1565,
40,
523
],
[
523,
1,
902
],
[
902,
23,
1475
]
],
[
[
1565,
1,
481
],
[
481,
40,
1563
],
[
1563,
23,
1475
]
],
[
[
1565,
24,
478
],
[
478,
24,
263
],
[
263,
23,
1475
]
],
[
[
1565,
24,
1040
],
[
1040,
64,
263
],
[
263,
23,
1475
]
]
] |
[
[
[
"Clonazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
]
] |
Clonazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Clonazepam may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Sodium citrate
Clonazepam (Compound) resembles Halazepam (Compound) and Halazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Clonazepam (Compound) resembles Quazepam (Compound) and Quazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
|
DB00860
|
DB08886
| 891 | 637 |
[
"DDInter1513",
"DDInter126"
] |
Prednisolone
|
Asparaginase Erwinia chrysanthemi
|
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
|
Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase.
|
Moderate
| 1 |
[
[
[
891,
24,
637
]
],
[
[
891,
24,
392
],
[
392,
24,
637
]
],
[
[
891,
40,
167
],
[
167,
24,
637
]
],
[
[
891,
24,
1385
],
[
1385,
63,
637
]
],
[
[
891,
63,
1274
],
[
1274,
24,
637
]
],
[
[
891,
62,
1018
],
[
1018,
24,
637
]
],
[
[
891,
25,
593
],
[
593,
24,
637
]
],
[
[
891,
1,
617
],
[
617,
24,
637
]
],
[
[
891,
64,
581
],
[
581,
24,
637
]
],
[
[
891,
25,
1510
],
[
1510,
25,
637
]
]
] |
[
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] |
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Prednisolone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.